







































































































Multiple	 Sclerosis	 (MS)	 is	 a	 chronic	 neurodegenerative	 disease	 of	 the	 central	 nervous	
system	 characterized	 by	 autoimmune-mediated	 mechanisms.	 T	 cells	 have	 been	
associated	 as	 central	 pro-inflammatory	 mediators	 in	 MS	 pathogenesis.	 In	 healthy	
individuals,	 immune	 cells	 adapt	metabolic	 programs	 like	mitochondrial	 respiration	 and	
glycolysis	based	on	their	function	and	inflammatory	phenotype.	However,	the	relevance	
of	 metabolic	 reprogramming	 and	 associated	 pro-inflammatory	 mechanisms	 in	 T	 cell	




T	 cells	 isolated	 from	 peripheral	 blood	mononuclear	 cells	 (PBMC).	 The	 results	 obtained	
demonstrated	decreased	mitochondrial	 and	glycolytic	 activity	 specific	 to	CD4+	T	 cells	 in	
the	MS	 patient	 cohort	 compared	 to	 the	HC	 participant	 cohort.	 Furthermore,	 increased	
CPT1a	 mitochondrial	 membrane	 protein	 levels	 were	 detected	 in	 CD4+	 T	 cell	
subpopulations	 in	 the	MS	patient	 cohort	 as	 assessed	 in	 comprehensive	 flow	 cytometry	
PBMC	phenotype	 investigations.	 The	 analysis	 of	 the	 CD4+	 CD25-	 CD127+	 conventional	 T	
cell	 subpopulation	moreover	 revealed	 a	 trend	 of	 decreased	 IL7-Rα	 expression	 levels	 in	
MS	patients.	Gene	expression	measurements	of	pro-inflammatory	and	metabolic	 genes	















Nervensystems,	 die	 durch	 auto-immun-bedingte	 Prozesse	 charakterisiert	 ist.	 T	 Zellen	
wurden	als	wesentliche	pro-inflammatorische	Mediatoren	mit	 der	Pathogenese	der	MS	
assoziiert.	 In	 gesunden	 Individuen	 passen	 Immunzellen	 ihren	 Metabolismus,	 wie	 die	
mitochondriale	 Atmung	 und	 Glykolyse,	 ihrer	 jeweiligen	 Funktion	 und	 ihrem	
inflammatorischen	 Phänotyp	 an.	 Im	 Krankheitsverlauf	 der	 MS	 ist	 die	 Bedeutung	 der	
metabolischen	 Anpassung	 und	 der	 damit	 verbundenen	 pro-inflammatorischen	
Mechanismen	 von	 T	 Zell-Subpopulationen	 noch	 nicht	 eindringlich	 erforscht.	 Um	 dieser	
Fragestellung	 nachzugehen	 wurden	 Relapsing	 Remitting	 MS	 (schubförmig,	 RRMS)	
Patienten	 und	 sorgfältig	 aufeinander	 abgestimmte	 gesunde	 Kontrollprobanden	 als	 Teil	
der	 Studie	Depression	 und	 Immunfuktion	 bei	 MS	 rekrutiert	 (n=62).	 Den	 Patienten	 und	
gesunden	 Kontrollprobanden	 wurde	 Nüchternblut	 entnommen,	 woraus	 periphäre	
mononukleäre	Blutzellen	(PBMC)	aufgearbeitet	wurden,	um	anschließend	CD4+	und	CD8+	
T	 Zellen	 zu	 isolieren.	 Die	 erzielten	 Ergebnisse	 zeigten	 CD4+	 T	 Zell-spezifische	
Verringerungen	 der	 mitochondrialen	 Atmung	 und	 glykolytischen	 Aktivität	 in	 der	 MS	
Patienten	 Kohorte	 im	 Vergleich	 zur	 Kohorte	 der	 gesunden	 Kontrollprobanden.	
Darüberhinaus	 wurden,	 zusätzlich	 zu	 den	 umfangreichen	 phänotypischen	
Charakterisierungen	 der	 PBMCs	 via	 Durchflußzytometrie,	 erhöhte	 Werte	 des	
mitochondrialen	 Membranproteins	 CPT1a	 in	 CD4+	 T	 Zell-Subpopulationen	 in	 der	 MS	
Patienten	Kohorte	detektiert.	Die	Analyse	der	CD4+	CD25-	CD127+	konventionellen	T	Zell-
Subpopulation	 ergab	 leicht	 erniedrigte	 Werte	 von	 IL7-Rα	 in	 MS	 Patienten.	
Genexpressionsanalysen,	 die	 mit	 pro-inflammatorischen	 und	 metabolischen	 Genen	
assoziiert	 sind,	 ergaben	 keine	 Veränderungen	 in	 den	 T	 Zell-Subpopulationen	 der	 MS	










































































































































Multiple	 Sclerosis	 (MS)	 is	 a	 chronic	 neurodegenerative	 disease	 of	 the	 central	 nervous	
system	 (CNS)	 characterized	by	 the	demyelination	of	neurons	believed	 to	be	 induced	by	
autoimmune	mechanisms.	Worldwide,	 approximately	 2.5	million	 people	 are	 diagnosed	
with	MS	and	about	200	000	people	in	Germany.	
Disease	 influencing	 factors	 include	environmental	and	genetic	 components	 leading	 to	a	
broad	 and	 heterogeneous	 clinical	 presentation.	 To	 date,	 magnetic	 resonance	 imaging	





over	 time.	 The	average	age	of	disease	onset	 is	 30	 years	 and	due	 to	 increasing	physical	





disease	 with	 an	 overall	 increasing	 disease	 burden	 including	 clinical	 disability	 and	 MRI	





patients	 show	 distinct	 clinical	 symptoms,	 most	 prominently	 optical	 neuritis,	 sensory	
deficits	 and	motor	 dysfunctions.	 As	 relapses	 increase	 over	 time,	 symptoms	 accumulate	




neuronal	 inflammation	 are	 redeemed	 by	 phases	 of	 remission	 during	 which	 symptoms	
decline	 or,	 especially	 in	 the	 early	 phases,	 subside	 to	 a	 great	 extent.	 However,	 with	
accumulating	 relapses,	 the	 disease	 burden	 increases,	 brain	 volume	 decreases	 and	
patients	 enter	 the	 third	 clinical	 stage,	 progressive	 MS.	 At	 this	 stage,	 neurological	
dysfunction	 progressively	 worsens	 without	 phases	 of	 remission	 occurring.	 Clinical	









during	 which	 symptoms	 with	 periods	 of	 relapses	 and	 neurological	 dysfunction	 as	 well	 as	 pro-
inflammation	 manifest	 and	 get	 replaced	 by	 periods	 of	 remission.	 	 The	 final	 clinical	 stage	 is	










visualized	 and	 observed	 over	 time	 allowing	 the	 measurement	 of	 disease	 burden	 and	
progression.	CNS	lesions	and	inflammation	are	a	hallmark	of	MS	and	are	accompanied	by	
a	blood	brain	barrier	(BBB)	leakage	allowing	the	scarcely	restricted	infiltration	of	immune	
cells	 from	 the	 peripheral	 blood	 stream	 [1].	 	 One	 of	 the	 first	 cell	 populations	 found	 in	
lesions	 inside	 the	 CNS	 include	 lymphocytes	 [3].	 Therefore,	 MS	 is	 presumed	 to	 be	 of	
autoimmune	etiology	initiated	by	over-	and	auto-reactive	T	lymphocytes	finally	targeting	





prevalence	 of	 developing	 depression	 of	 up	 to	 50%	 [4].	 Studies	 have	 shown	 strong	
associations	 between	 an	 increased	 inflammatory	 profile	 in	MS	 patients	 with	 increased	
fatigue	 and	 depression	 scores	 further	 contributing	 to	 the	 inflammatory	 processes	
observed	in	MS	patients	[5]–[7].	Importantly,	symptoms	can	be	very	diverse	and	depend	
on	the	degree	of	disability	and	overall	disease	burden	of	a	patient.	












maturation,	 development	 and	 homeostasis	 and	 downstream	 activation	 of	 the	 janus	






The	 IL2-Rα	 is	 upregulated	 on	 activated	 T	 cells	 and	 therefore	 essential	 in	 cellular	
proliferation,	 survival	 and	 T	 cell	 homeostasis	 [12],[13].	 Taken	 together,	 genetic	 risk	
factors	 for	 MS	 hint	 toward	 strong	 associations	 with	 immune	 regulation,	 however,	 no	
single	genes	have	been	defined	to	be	involved	in	causing	MS.	
Another	contributor	 to	MS	development	and	progression	are	environmental	 influences.	
One	of	 the	most	widely	discussed	environmental	 factor	 in	MS	disease	 is	 the	protective	
effect	of	ultra	violet	(UV)	radiation	exposure.	Especially	early	in	life	before	the	age	of	20,	
elevated	 UV	 radiation	 exposure	 and	 with	 that	 increased	 vitamin	 D	 levels	 have	 been	
shown	 to	 reduce	 MS-risk	 later	 in	 life	 [14].	 Vitamin	 D	 signaling	 greatly	 affects	 anti-
inflammatory	immune	cell	pathways	via	T	and	B	lymphocyte	suppression	and	regulatory	T	




The	effects	of	 sex	differences	and	hormones	have	also	been	 studied	extensively	 in	MS.	
The	2.5:1	ratio	of	females:males	affected	by	MS	is	striking.	This	ratio	has	been	explained	
with	parent	of	origin	effects	where,	 for	example	disease	associations	 like	 the	 risk	allele	
HLA-DRB1*15:01	 show	a	 stronger	 association	with	 females	 [17].	 Additionally,	 X-	 and	 Y-
chromosome-linked	 genes	 have	 been	 shown	 to	 contribute	 to	 gene-dosage	 effects	 and	
immune	 regulation	 of	 innate	 and	 adaptive	 immune	 responses	 [18].	 Furthermore,	
hormone	 regulation	 greatly	 affects	 cells	 of	 the	 innate	 and	 adaptive	 immune	 system	
displaying	 distinct	 differences	 and	 adaptations	 in	 females	 and	 males	 (particularly	
estrogen	and	testosterone,	 respectively).	This	effect	 is	most	prominent,	considering	 the	
strong	protective	effect	of	pregnancy	from	relapses	[19].		
Taken	 together,	 genetics,	 environmental	 influences,	 sex	 and	 hormones	 allow	 a	 deeper	










Current	 immune-modulatory	 medications	 to	 treat	 RRMS	 are	 targeted	 at	 innate	 and	
adaptive	immune	cells.	They	suppress	pro-inflammatory	signaling	and	have	become	more	
advanced	in	the	last	decade	with	to	date	more	than	ten	drugs	approved	by	the	American	
Food	 and	 Drug	 Administration	 (FDA).	 Baecher-Allan	 and	 colleagues	 most	 recently	
published	an	extensive	review	summarizing	current	drugs,	 their	specific	 targets	and	the	
mechanisms	 of	 action	 [2].	 	 In	 summary,	 the	modes	 of	 action	 include	 the	 trapping	 of	 T	
lymphocytes	inside	the	lymph	nodes	and	with	that	prevention	of	T	lymphocyte	migration	
via	the	BBB	into	the	CNS,	the	promotion	of	T	regs	and	decrease	of	MS-disease	 inducing	
Th1/Th17	 cells	 as	 well	 as	 the	 inhibition	 and	 depletion	 of	 B	 lymphocytes.	 Considering	
efficacy,	 side	 effects,	 relapse	 history	 and	 CNS	 lesions,	 the	 clinician	 and	 patient	 decide	
which	drugs	to	use.	The	efficacy	of	the	drug	is	measured	by	the	reduction	in	relapses	and	
a	 decrease	 of	 inflammation.	Using	MRI	 scans,	 disease	 progression	 and	brain	 atrophy	 is	
determined	[20].			
Almost	 all	 of	 the	 FDA	 approved	 drugs	 target	 the	 relapsing	 inflammatory	 stage	 and	 are	
largely	not	effective	 in	 the	progressive	 forms	of	MS.	Furthermore,	 to	date,	medications	
are	effective	in	limiting	relapses,	but	do	not	fully	prevent	disease	progression.	
Broadening	 the	 understanding	 of	 the	molecular	mechanisms	 of	 immune	 activity	 in	MS	
may	allow	a	deeper	understanding	of	causative	mechanisms	underlying	the	disease.		
1.2 Principals	of	the	Immune	System	








like	 the	 central	 nervous	 system	 and	 (neuro-)	 endocrine	mechanisms	 as	 well	 as	 energy	
demand	 and	 response	 signaling	 pathways.	 It	 is	 classified	 into	 innate	 and	 adaptive	
immunity,	 which	 constantly	 interact	 to	 initiate	 effective	 defense	mechanisms	 involving	
humoral	(non-cellular)	and	cellular	structures.	The	cellular	components	of	the	blood	arise	
from	 pluripotent	 hematopoetic	 stem	 cells	 (HSC)	 in	 the	 bone	marrow	 that	 possess	 the	
ability	 to	 develop	 into	 common	 lymphoid	 progenitor	 cells	 (T	 and	 B	 lymphocytes	 and	
natural	 killer	 cells)	 as	 well	 as	 common	 myeloid	 progenitor	 cells	 (monocytes,	 dendritic	
cells,	granulocytes).	Peripheral	blood	mononuclear	cells	(PBMCs)	are	composed	of	about	
25-60%	CD4+	T	lymphocytes,	5-30%	CD8+	lymphocytes,	5-10%	B	lymphocytes,	10-30%	NK	




line	 of	 defense	 against	 pathogens	 like	 bacteria,	 viruses,	 worms	 or	 fungi.	 Examples	 for	
innate	 immune	 cells	 are	 neutrophils,	 basophils,	 eosinophils	 (all	 granulocytes),	 natural	
killer	 (NK)	 cells	 and	monocytes.	 They	 circulate	within	 the	 peripheral	 blood	 stream	 and	
constantly	 monitor	 for	 invading	 pathogens.	 Humoral	 components	 include	 the	
complement	 system,	 cytokines,	 chemokines	 and	 pattern	 recognition	 receptors	 (PRRs).	
Cytokines	 are	 small	 proteins	 involved	 in	 cell-specific	 signaling	 and	 communication.	 A	
subtype	of	cytokines	are	chemokines,	which	possess	the	ability	to	recruit	cells	to	the	site	




TLRs	 have	 been	 identified	 [22],	 each	 able	 to	 recognize	 one	 or	 multiple	 ligands,	 e.g.	
microbial	motifs	and	debris	from	necrotic	cells.		






additional	 immune	 cells	 causing	 further	 pro-inflammatory	 responses	 and	 pathogen	
clearance.		
Additionally,	 most	 innate	 immune	 cells	 function	 as	 antigen	 presenting	 cells	 (APCs).	
Following	the	recognition	by	their	TLR,	APCs	can	present	processed	antigen	via	their	MHC	
class	 II	 for	 antigen	 recognition	 by	 T	 lymphocytes	 of	 the	 adaptive	 immune	 system.	
Furthermore,	MHC-II	presentation	can	also	occur	after	phagocytosis,	 the	engulfment	of	
cells	or	particles,	of	pathogens	or	 infected	cells.	 The	 interaction	of	 innate	and	adaptive	







and	 anti-viral	 immune	 responses	 [23].	 They	 predominantly	 detect	 cells	 that	 lack	 MHC	
class	I	expression	and	with	that	the	identification	of	a	cell	as	self.	The	main	functions	of	
NK	 cells	 include	 the	 secretion	of	 immune	 activating	 cytokines	 and	 chemokines	 and	 the	
killing	of	infected	or	transformed	cells	via	pathways	including	perforin/granzyme	or	death	




(INFγ)	 and	 granulocyte-monocyte	 colony	 stimulating	 factor	 (GM-CSF)	 and	 requires	 the	
presence	of	assessor	cytokines	 like	 IL-2	and	 IL-12,	 IL-2	and	 IL-18	or	 IL-15	and	 IL-18	[28].	
Consequently,	 NK	 cell	 activation	 is	 coupled	 to	 assessor	 processes	 safeguarding	 over-
reactivity.	
Based	on	 their	 function,	cytokine	secretion	profile	and	cell	 surface	 receptor	expression,	







INFγ	 is	 the	 signature	 cytokine	 of	 CD56bright	 NK	 cells	 and	 known	 to	 shape	 Th1-mediated	




Taken	together,	NK	cells	play	an	 important	role	 in	 innate	 immune	response	and	cellular	
activation	as	well	as	in	the	induction	of	adaptive	immune	mechanisms.		
1.2.1.2 Monocytes		
Monocytes	 are	 central	APCs	of	 the	 innate	 immune	 system.	 	 They	 get	 released	 into	 the	
periphery	where	three	monocyte	subpopulations	have	been	characterized	based	on	their	
cell	 surface	 receptor	 expression:	 classical	 monocytes	 (CD14++	 CD16-),	 intermediate	
monocytes	 (CD14++	 CD16+)	 and	 non-classical	 monocytes	 (CD14+	 CD16++)	 [32].	 After	
circulating	 in	 the	 blood,	 they	 reach	 tissue	where	 they	 differentiate	 and	 further	mature	
into	tissue	resident	dendritic	cells	(DC)	or	macrophages.		
The	main	functions	of	monocytes	include	pro-inflammatory	cytokine	production	following	






Once	 they	are	activated,	 they	 release	pro-inflammatory	 cytokines	and	with	 that	 induce	
the	transmigration	of	other	innate	and	adaptive	immune	cells	to	the	site	of	inflammation.	
Depending	on	the	intruding	pathogen,	monocytes	have	been	shown	to	be	able	to	induce	






Taken	 together,	 monocytes	 display	 an	 essential	 role	 in	 rapid	 innate	 immune	 response	
mechanisms	 and	 are	 key	 components	 in	 adaptive	 immune	 cell	 activation,	 proliferation	
and	suppression.		
1.2.2 The	Adaptive	Immune	System	 	
The	 adaptive	 immune	 system	 compromises	 defense	 mechanisms	 that	 are	 acquired,	
develop	from	the	time	of	birth	and	evolve	over	the	course	of	a	lifetime.	As	described	for	
innate	 immune	 responses,	 adaptive	 immunity	 also	 entails	 cellular	 and	 humoral	
components.	However,	contrary	to	innate	immunity,	adaptive	immunity	is	highly	antigen-
specific.	Main	cell	 types	constituting	adaptive	 immunity	 include	T	and	B	 lymphocytes.	T	
lymphocyte	subpopulations	include	helper	and	cytotoxic	T	lymphocytes	with	specific	cell	
surface	 receptor	 expression	 and	 antigen-specific	 functions.	 B	 lymphocytes	 produce	
antigen-specific	 antibodies,	 which	 are	 part	 of	 the	 humoral	 structures	 in	 adaptive	
immunity.	Furthermore,	both,	T	and	B	lymphocytes,	possess	the	ability	to	form	memory	
cells	 after	 antigen	 clearance,	 a	 crucial	 process	 that	 allows	 an	 immediate	 immune	
response	during	a	secondary	infection	with	the	same	antigen.		
The	ability	of	specialized	cell	subpopulations	to	respond	to	specific	antigens	and	generate	




to	 the	 thymus	 (thymocytes)	 and	mature	 into	 functional	 CD4+	 and	 CD8+	 T	 lymphocytes	




and	a	variable	 region.	The	variable	 region	 is	 the	site	of	antigen-recognition	and	specific	
for	each	T	cell.	During	T	cell	development,	the	α	and	β	genes	of	the	variable	region	of	the	




diversity-joining	 (V-D-J,	 β-chain)	 gene	 segments.	 This	 process	 allows	 the	 tremendous	








and	 foreign	 antigen	 via	 their	 TCR.	 Briefly,	 during	 the	 first	major	 stage	 of	 thymic	 T	 cell	
differentiation,	 double-negative	 CD4-	 CD8-	 T	 cells	 undergo	 TCR	 rearrangement.	 This	
allows	 them	 to	 progress	 to	 the	 second	 major	 stage	 of	 differentiation	 where	 they	 are	
termed	double-positive	T	cells	expressing	both	CD4	and	CD8	co-receptors.	At	this	point,	
APCs	 present	 a	multitude	 of	 antigens	 and	 self-peptides	 via	MHC	 classes	 I	 and	 II	 to	 the	
premature	T	cells.	Now,	positive	and	negative	selection	occurs	during	which	highly	self-
reactive	T	cells	(binding	to	self-antigens	on	the	MHCs)	and	T	cells	that	do	not	bind	MHC	





tissue,	 tonsils	 or	 adenoids).	 Their	 main	 function	 is	 immune	 surveillance.	 Once	 they	
encounter	their	specific	antigen,	they	mature	into	functional	helper	or	effector	T	cells.		
T	 cell	 activation	 requires	 the	 binding	 of	 the	 antigen-specific	 TCR-complex	 to	 the	MHC-
antigen	complex	on	the	cell	surface	of	APCs.	 	The	MHC-complex	 is	composed	of	the	co-
stimulatory	 receptors	 CD80	 or	 CD86	 (binding	 to	 CD28	 on	 the	 TCR)	 as	 well	 as	 CD40	
(binding	 to	 CD40	 L	 on	 the	 TCR).	 CD4+	 T	 cells	 recognize	 antigens	 from	 pathogens	 like	
extracellular	bacteria,	worms	or	toxins	that	have	been	processed	by	APCs	and	presented	
on	 their	 MHC	 class	 II.	 In	 contrast,	 CD8+	 T	 cells	 recognize	 antigens	 from	 intracellular	
















differentiation	 to	 memory	 T	 cells,	 CCR7+	 naïve	 T	 cells	 (TN)	 down-regulate	 the	 CD45RA	
isoform	 and	 express	 the	 CD45RO	 isoform.	 TCM	 are	 CCR7+,	 have	 high	 proliferative	
capacities	and	lower	effector	functions.	TEM	are	CCR7-,	resident	in	peripheral	tissues	and	
possess	 the	ability	 to	quickly	 adapt	 a	CD4+	effector	or	CD8+	 cytotoxic	 T	 cell	 phenotype.	
The	 third	 memory	 subtype	 are	 TEMRA,	 which	 are	 CCR7-,	 show	 low	 proliferative	 and	
functional	capacities	and	characteristics	of	senescent	cells	[39].		
	
Taken	 together,	 CD4+	 and	 CD8+	 memory	 T	 cell	 subpopulations	 monitor	 and	 patrol	 the	
body	for	 intruding	pathogens	in	tissues	and	the	periphery.	They	are	highly	effective	and	
time-efficient	during	a	secondary	immune	response	to	a	previously	targeted	pathogen	in	
the	 primary	 immune	 response.	 This	 is	 the	 essence	 of	 adaptive	 immunity	 allowing	
pathogen-specific	immune	responses.		
1.2.2.1.1 CD4+	T	lymphocytes		
Upon	 activation,	 CD4+	 TN	 differentiate	 into	 effector	 T	 cells	 including	 helper	 T	 cell	 (Th)	
types	Th1,	 Th2,	 Th17	and	Th1/17.	Helper	T	 cells	mediate	 cellular	 and	humoral	 immune	
responses	 specific	 to	 the	 intruding	 pathogen.	 They	 are	 characterized	 based	 on	 their	
chemokine	receptor	and	cytokine	profile	as	well	as	individual	transcription	factors	(Table	







transcription	 factors	T-bet,	 STAT1	and	STAT4	 [40].	 Th1	 cells	 are	 characterized	based	on	
the	 chemokine	 receptors	 CXC-chemokine	 receptor	 (CXCR)	 3	 and	 chemokine	 receptor	





homologous	molecule	 expressed	 on	 Th2	 cells	 (CRTh2)	 [43].	 They	 secrete	 IL-4,	 IL-5,	 IL-9	
and	 IL-13	and	stimulate	histamine-	and	heparin-secreting	mast	 cells	 contributing	 to	 the	
elimination	 of	 extracellular	 pathogens	 like	 bacteria	 or	 worms.	 Furthermore,	 Th2	 cell	
stimulation	 leads	 to	 the	 activation	 of	 B	 lymphocytes	 inducing	 antigen-specific	 antibody	
production.	
Th17	cells	induce	a	strong	pro-inflammatory	immune	response	to	extracellular	pathogens	





neutrophil	 activation,	 which	 promotes	 a	 fast	 line	 of	 defense	 via	 the	 release	 of	 anti-
microbials,	 the	 elimination	 of	 pathogens	 by	 phagocytosis	 and	 the	 induction	 of	
chemotaxis.	 Th17	 immune	 response	mechanism	 can	 be	 inhibited	 by	 Th2	 cells,	 thereby	
preventing	an	overreaction	of	the	immune	system	and	with	that	a	damage	of	self-tissue.	
Th1/17	 cells	 have	 been	 described	 as	 a	 transitional	 state	 between	 Th17	 and	 Th1	 cells	



















subtypes	 including	 the	 chemokine	 receptor	 expression	 profiles	 characteristic	 for	 each	












































































IL:	 interleukin,	 TF:	 transcription	 factor,	 Th:	 helper	 T	 cell,	 IFN-γ:	 interferon	 γ,	 GM-CSF:	
granulocyte-macrophage	 colony-stimulating	 factor,	 mTOR:	 mechanistic	 target	 of	
rapamycin,	ERR:	estrogen	receptor,	HIF-1α:	hypoxia-inducible	factor-1α,	FoxP3:	forkhead	
P3,	 TGF:	 transforming	 growth	 factor,	 AMPK:	 AMP-activated	 protein	 kinase,	 TN:	 naïve	 T	
cells,	CM:	central	memory,	EM:	effector	memory,	TEMRA:	terminally	differentiated	effector	
memory	 cells	 re-	 expressing	 CD45RA,	 TNF-α:	 tumor	 necrosis	 factor-α,	 CCR:	 Chemokine	
Receptor,	CXC:	CXC-Chemokine	Receptor,	CRTh2:	Chemoattractant	receptor-homologous	




MHC	 class	 I	 molecules	 on	 APCs	 via	 their	 CD8	 TCR	 complex	 and	 are	 very	 potent	 pro-
inflammatory	immune	activators	(described	in	1.2.2.1).	They	differentiate	and	proliferate	






bacteria	 and	 cancer	 cells,	 CD8+	 T	 cells	 secrete	 perforin,	 granzyme	 and	 granulolysin	
inducing	a	strong	 immune	attack.	To	prevent	an	 immune	overreaction,	cytotoxic	T	cells	







somewhat	 elusive.	 CD8+	 CCR4+	 CCR6-	 CXCR3-	 T	 cells	 are	 predominantly	 found	 in	 the	
epithelium	and	 lung	 [49]	and	are	 involved	 in	Th2-mediated	 immunity	 [50].	 	CD8+	CCR6+	
CCR4-	CXCR3-	T	cells	are	mainly	located	in	the	gut	and	have	been	shown	to	be	essential	in	
Th17-mediated	 immune	 responses,	 while	 CD8+	 CXCR3+	 CCR4-	 CCR6-	 T	 cells	 display	 key	
immune	functions	in	Th1	immunity	[50].	
CD8+	 cytotoxic	 T	 cells	 act	 on	 pathogen	 infected	 cells	 or	 neoplastic	 cells	 by	 releasing	
granzyme,	granulolysin	and	perforin.	These	factors	are	released	from	granules	within	the	
cytoplasm	 of	 cytotoxic	 T	 cells	 and	 are	 exerted	 onto	 the	 target	 cells.	 They	 induce	
apoptosis,	 form	holes	 in	 the	 target	 cell	membranes,	 inhibit	 virus	 replication	 and	 act	 as	
anti-microbials	by	creating	a	pro-inflammatory	micro-environment.	
1.2.2.2 B	lymphocytes	-	development,	differentiation	and	activation	
Just	 like	 T	 cells,	 B	 lymphocytes	 (subsequently	 termed	 B	 cells)	 are	 lymphocytes	 derived	
from	 pluripotent	 hematopoetic	 stem	 cells	 in	 the	 bone	 marrow	 and	 are	 part	 of	 the	
adaptive	immune	system.	B	cells	and	the	immunoglobulins	(Ig,	also	known	as	antibodies)	
they	 produce	 make	 up	 an	 essential	 part	 of	 humoral	 immunity	 protecting	 against	 an	
enormous	variety	of	pathogens.	The	B	cell	antibody	repertoire	entails	antibodies	that	can	
recognize	more	than	5x1013	specificities	 [51].	B	cells	can	produce	five	different	 types	of	






underlying	 the	 production	 of	 antibodies	 resemble	 that	 of	 the	 TCR	 on	 T	 cells.	 Briefly,	
during	 cellular	 development	 in	 the	bone	marrow,	B	 cells	 undergo	 the	 following	 stages:	
stem	cell,	early	pro-B	cell,	late	pro-B	cell,	large	pro-B	cell,	small	pre-B	cell	and	immature	B	
cell	[52].	When	the	precursor	forms	of	the	B	cells	undergo	these	stages,	rearrangements	
of	 the	 variable	 (V),	 joining	 (J)	 and	 diversity	 (D)	 regions	 of	 the	 heavy	 chain	 and	 VJ	
rearrangement	 of	 the	 light	 chain	 occurs.	 Heavy-chain	 rearrangement	 occurs	 after	 the	
early	pro-B	cell	stage	and	its	success	is	tested	selecting	for	functional	heavy	chains.	If	the	















mature	 naïve	 B	 cells.	 Mature	 naïve	 B	 cells	 are	 further	 characterized	 as	 CD20+	 CD3-	
lymphocytes	[54]	and	have	been	described	to	secrete	the	immunosuppressive	cytokine	IL-
10	 [55].	 CD20	 is	 expressed	 from	 the	 pre-B	 cell	 stage	 until	 the	mature	 naïve	 as	well	 as	
memory	 B	 cell	 stage,	 however,	 plasma	 cells	 lack	 CD20.	 Mature	 naïve	 B	 cells	 circulate	
between	 lymphoid	vessels	and	the	blood	stream	where	they	encounter	APCs	as	well	as	
helper	T	cells	and	patrol	for	intruding	pathogenic	antigens.		
Interestingly,	 mature	 B	 cells	 undergo	 a	 process	 termed	 somatic	 hypermutation.	 In	
addition	to	immunoglobulin	gene	rearrangement	in	the	BM,	this	highlights	a	second	step	










recognize	and	bind	antigen	directly	 via	 their	BCR	along	with	 co-receptors	 and	have	 the	
ability	to	bind	non-protein	antigens	like	foreign	polysaccharides	and	DNA	independent	of	
T	cell	engagement	 [56].	Nevertheless,	B	cells	can	bind	antigens	by	their	antigen-specific	




cell-mediated	 initiation	 of	 activation,	 proliferation	 and	 differentiation	 following	 antigen	
presentation	 by	 T	 cells	 [57].	 Once	 the	 B	 cell	 recognizes	 its	 specific	 antigen,	 the	 cell	
undergoes	clonal	expansion	and	develops	into	an	antibody-producing	plasma	cell	fighting	
off	 the	pathogen	and	activating	additional	 immune	mechanisms	and	cells	of	 the	 innate	
and	adaptive	immune	system.		
In	 addition	 to	 B	 cells	 undergoing	 clonal	 expansion,	 antigen-specific	memory	 B	 cells	 are	
formed,	which	able	to	effectively	and	efficiently	fight	re-occurring	antigens	[58].	These	
long-lived	memory	B	cells	are	CD20+	and	able	 to	persist	 for	years	 [59].	They	have	been	
described	to	be	CD27+	and	produce	pro-inflammatory	cytokines	like	IL-12,	lympho	toxin	α	
(LTα)	and	TNF-α	[55].	
In	 summary,	 B	 cells	 are	 very	 potent	 antigen-specific	 lymphocytes	 with	 a	 tremendous	
antigen	recognition	repertoire	that	is	vital	in	complementing	T	cell	immune	responses.		
The	described	developmental	 stages	and	numerous	 functions	of	B	cells	 require	 the	 fine	








The	 word	metabolism	 is	 derived	 from	 the	 Greek	 word	 μεταβολισμός	 (metavolismós),	
which	means	 change.	 	 Immune	 cells	 have	 numerous	 specifications,	 functionalities	 and	
responsibilities	and	with	that	need	to	display	very	distinct	metabolic	profiles	to	meet	their	
individual	 tasks	 and	 fulfill	 their	 target	 functions.	 Therefore,	 the	 ability	 to	 adapt	 and	
change	 their	metabolic	 profile	 is	 crucial	 for	healthy	 immune	 response	mechanisms	and	
host	survival.	
One	of	 the	 first	 researchers	analyzing	 cellular	metabolic	 function	was	Otto	Warburg.	 In	
1956,	 he	 described	 that	 even	 under	 aerobic	 conditions	 cancer	 cells	 heavily	 depend	 on	
glycolysis	instead	of	oxidative	phosphorylation	(OXPHOS)	to	meet	their	increased	energy	
demand-	an	observation	that	has	subsequently	been	termed	the	Warburg	Effect	[60],[61].	





Cells	 are	 regulated	 by	 extrinsic	 and	 intrinsic	mechanisms	 and	 therefore	modulate	 their	
specific	 activities	 and	 metabolic	 pathways	 based	 on	 their	 requirements	 for	 survival,	
growth	 or	 development.	 The	 ability	 to	 use	 and	 switch	 between	 different	 pathways	 to	
generate	 energy	 from	nutrients	 like	 sugars,	 proteins	 and	 fats	 are	 key	 characteristics	 of	
cellular	energy	metabolism.	Typically,	the	energy	is	stored	in	the	chemical	bonds	of	these	
nutrients	and	the	catabolism	(break	down)	of	these	bonds	releases	energy,	which	is	used	





The	 cytosol	 is	 defined	 as	 the	 liquid	 inside	 the	 cell	 and	 is	 surrounded	 by	 the	 cell	




metabolism	 including	 glutaminolysis	 take	 place	 in	 the	 cytosol.	 It	 separates	 numerous	
compartments	within	 the	 cell,	with	distinct	 functions	 and	 responsibilities.	One	of	 these	





the	 inside	 of	 the	 mitochondria,	 the	 mitochondrial	 matrix.	 Cristae	 are	 the	 site	 of	 ETC	
complexes	and	energy	production	in	the	form	of	ATP.		
To	 meet	 the	 cell’s	 energy	 demand,	 mitochondria	 possess	 the	 ability	 to	 adapt	 their	
morphology.	 They	 can	 fuse	 together,	 a	 process	 termed	 mitochondrial	 fusion	 and	
observed	 to	 be	 required	 in	 fatty	 acid	 oxidation	 (FAO)	 and	memory	 T	 cell	 development	
[62],[63].	During	 fusion,	mitochondrial	cristae	move	further	apart	and	thereby	decrease	
ETC	 efficiency	 and	 energy	 production	 in	 the	 form	 of	 ATP.	 Additionally,	 the	 division	 of	
mitochondria,	 termed	mitochondrial	 fission,	 has	 been	 observed	 in	 effector	 T	 cells	 and	
increases	 mitochondrial	 energy	 production.	 Fission	 induces	 mitochondrial	 cristae,	 and	
with	 that	 ETC	 complexes,	 to	 move	 closer	 together	 and	 thereby	 allows	 for	 a	 greater	
efficiency	of	energy	production,	specifically,	ATP	generation	[62],[63].		
Fusion	and	fission	are	also	required	for	the	regulation	of	mitophagy.	Mitophagy	has	first	
been	 described	 by	 Lemaster	 and	 colleagues	 as	 the	 process	 of	 degradation	 of	 damaged	
mitochondria	 [64].	 In	 cellular	 division,	 fission	 processes	 allow	 the	 equal	 distribution	 of	
mitochondria	 between	 cells,	 induce	 the	 segregation	 of	 damaged	 mitochondria	 and	
initiation	of	mitophagy	 [65],[66].	A	most	 recent	 comprehensive	 review	by	Williams	and	
Ding	 summarizes	 the	 complex	 field	 of	 mitophagy	 and	 the	 underlying	 molecular	
mechanisms	and	pathophysiological	roles	[67].	Briefly,	the	authors	describe	nuclear	and	
mitochondrial	 genes	 involved	 in	 mitophagy	 processes	 and	 the	 relevance	 of	 mitophagy	
processes	 in	 innate	 and	 adaptive	 immunity.	 E.g.,	 in	 T	 cells,	 mitophagy	 is	 essential	 for	
cellular	 differentiation	 and	 mitophagy	 deficiency	 has	 been	 shown	 to	 increase	










Mitochondria-associated	 membranes	 (MAMs)	 directly	 connected	 mitochondria	 to	 the	









are	 taken	up	 from	 the	 interstitial	 fluid	outside	 the	 cell	 into	 the	 cytosol.	 Subsequently,	 they	 get	
catabolized	 via	 numerous	 chemical	 reactions	 yielding	 energy-rich	 ATP,	 NADH	 and	 FADH2	
molecules.	Glycolysis,	PPP,	glutaminolysis	(all	taking	place	in	the	cytosol),	FAO,	ETC	and	OXPHOS	















In	 order	 for	 FAO	 to	 commence,	 fatty	 acids	 need	 to	 be	 activated	 and	 subsequently	
transferred	 from	 the	 cytosol	 via	 the	mitochondrial	membrane	 into	 the	mitochondrion.	
The	activation	of	fatty	acids	involves	an	enzyme-mediated	reaction	in	the	cytosol	during	
which	acetyl-coenzyme	A	(acetyl-CoA)	 is	bound	to	the	fatty	acid.	Short-chain	 fatty	acids	
(between	 2	 and	 6	 carbon	 atoms	 in	 size)	 can	 diffuse	 into	 the	 mitochondria.	 However,	
medium-	 and	 long-chain	 fatty	 acids	 (larger	 than	 6	 carbon	 atoms)	 cannot	 diffuse	 into	
mitochondria	and	require	a	specific	transporter	[72],[74].	
The	 central	molecule	 facilitating	 this	 transfer	 is	 CPT1a	 (Carnitine	 palmitoyltransferase	 I	
isoform	a),	which	 is	 located	 in	 the	mitochondrial	membrane.	CPT1a	 is	a	member	of	 the	






This	 allows	 the	 conjugated	 fatty	 acid	 acyl-CoA	 to	 be	 shuttled	 into	 the	 mitochondrion	
where	it	is	transferred	back	to	fatty	acid	acyl-CoA	by	CPT2	(Carnitine	palmitoyltransferase	
2)	 [76].	 Now,	 FAO	 can	 begin	 yielding	 acetyl-CoA,	 NADH	 (Nicotinamide	 Adenine	
Dinucleotide	 H)	 and	 FADH2	 (Flavin	 Adenine	 Dinucleotide	 H2).	 The	 lipid	 synthesis	
intermediate	 malonyl-CoA	 inhibits	 CPT1a	 once	 fatty	 acid	 synthesis	 (FAS)	 occurs	 in	 a	
nutrient	 abundant	 environment.	 Therefore,	 the	 transfer	 of	 fatty	 acids	 via	 CPT1a	 is	 the	
rate-limiting	step	and	CPT1a	the	key	regulatory	protein	in	FAO.	
Compared	to	glycolysis,	FAO	is	very	efficient	and	allows	the	generation	of	large	amounts	
of	 ATP	 from	 complex	 fatty	 acid	 molecules.	 For	 example,	 the	 complete	 FAO	 of	 one	








During	 oxidative	 phosphorylation	 (OXPHOS),	 electrons	 are	 transported	 down	 an	
electrochemical	proton	gradient	of	the	electron	transport	chain	(ETC).	The	ETC	is	made	up	
of	complex	I	to	complex	V	and	is	integrated	into	the	inner	mitochondrial	membrane	[80]	
[81].	 It	 is	a	 series	of	 redox	 (reduction	and	oxidation)	 reactions	performed	by	numerous	
enzymes	 during	 which	 electrons	 are	 transferred	 from	 electron	 donors	 to	 acceptors,	
allowing	the	transfer	of	hydrogen	protons	(H+)	from	the	mitochondrial	matrix	to	the	inter-
membrane	 space.	 This	 generates	 a	 proton	 gradient,	 which	 is	 used	 for	 ATP	 synthesis.	
Importantly,	 the	 process	 of	 ADP	 (adenosine	 diphosphate)-phosphorylation	 to	 form	
energy-rich	 ATP	 requires	 the	 presence	 of	 molecular	 oxygen	 (O2)-	 hence	 it	 is	 termed	





protons	 (H+),	 which	 are	 pumped	 into	 the	 mitochondrial	 inter-membrane	 space.	 The	
reaction	 also	 yields	 electrons,	 which	 are	 transported	 to	 the	 next	 complex	 in	 the	 ETC,	
complex	 II.	 	 The	 function	 of	 complex	 I	 can	 be	 inhibited	 by	 e.g.	 rotenone	 (Table	 2)	
preventing	the	electron	transfer	to	complex	II	and	causing	an	accumulation	of	electrons	in	
the	mitochondrial	matrix	 as	well	 as	 the	 inhibition	of	 hydrogen	proton	 transfer	 into	 the	
inter-membrane	space.		
Complex	 II	 (succinate	 dehydrogenase)	 is	made	 up	 of	 four	 subunits	 and	 the	 succeeding	
complex	in	the	ETC.	In	addition	to	electrons	derived	from	complex	I,	complex	II	receives	













III	 and	 transfers	 them	 to	 molecular	 oxygen,	 which	 yields	 a	 H2O	 molecule.	 During	 this	
process,	hydrogen	protons	are	transferred	into	the	inter-membrane	space.		
The	 uneven	 difference	 in	 hydrogen	 proton	 concentration	 between	 the	 mitochondrial	
matrix	 and	 inter-membrane	 space	 is	 used	 by	 ATP-synthase,	 complex	 V,	 of	 the	 ETC.	 	 It	
constitutes	 two	 regions	with	numerous	 subunits	and	 is	 the	 final	 step	of	 the	ETC	during	
which	ATP-generation	occurs	from	ADP	and	phosphate.	The	hydrogen	protons	are	passed	
via	the	ATP-synthase	into	the	matrix	allowing	ATP	synthesis	to	occur.	The	process	of	ADP-





Figure	 3:	 Display	 of	 the	 mitochondrial	 electron	 transport	 chain.	 The	 electron	 transport	 chain	
(ETC)	 is	 located	at	 the	 inner	membrane	of	mitochondria.	Electrons	are	donated	 to	complex	 I	of	
the	ETC	and	transported	in	a	series	of	redox	reactions	to	complex	II,	III,	IV	and	V.	This	allows	the	





















within	 the	 mitochondrion	 that	 require	 the	 presence	 of	 molecular	 oxygen	 and	 yield	
tremendous	 amounts	 of	 energy-rich	 ATP	 molecules	 that	 the	 cell	 can	 use	 for	 any	





(C6H12O6)	 is	 catabolized	 in	 consecutive	 reactions	 into	 pyruvate	 along	 with	 numerous	
byproducts.	The	glycolytic	pathway	begins	with	the	uptake	of	extracellular	glucose	from	
the	 interstitial	 fluid,	 the	 immediate	 cellular	 microenvironment	 surrounding	 the	 cell.	
Glucose	molecules	require	a	transporter	in	order	to	cross	the	cell	membrane.	One	of	the	




The	 intracellular	 processing	 of	 glucose	 in	 the	 glycolytic	 pathway	 entails	 a	 series	 of	
enzymatic	 reactions	 yielding	 pyruvate	molecules.	Under	 anaerobic	 conditions,	 pyruvate	
can	 be	 processed	 into	 lactate	 and	 ethanol.	 Under	 aerobic	 conditions,	 pyruvate	 is	
processed	 to	 acetyl-CoA	 and	 entered	 into	 the	 TCA	 cycle,	 which	 takes	 place	 in	 the	





However,	anaerobic	glycolysis	 is	 less	efficient	 in	 the	generation	of	energy-rich	ATP.	The	
catabolism	of	one	glucose	molecule	 yields	 two	ATPs	during	anaerobic	glycolysis	 and	36	
ATPs	 if	processed	via	the	TCA	cycle	and	ETC	respiration	[76].	Lactate	and	CO2	are	waste	
products	 that	 are	 secreted	 by	 the	 cell	 and	 are	 associated	 with	 an	 increased	 acidic	
microenvironment	[86].		
Nevertheless,	there	are	central	benefits	of	glycolysis,	including	the	generation	of	the	co-
factor	 NADH,	 which	 is	 essential	 in	 cellular	 anabolism.	 Furthermore,	 glycolysis	 provides	
intermediates	 for	 the	 biosynthesis	 of	 fatty	 acids,	 amino	 acids	 as	 well	 as	 ribose	 for	
nucleotides.	 Consequently,	 cellular	 dependency	 of	 glycolysis	 has	 been	 observed	 in	
growing,	activated	and	proliferating	cells,	which	require	large	amounts	of	biomaterial.		
1.3.1.4 Tri-citric	Acid	Cycle		
An	 additional	 major	 cellular	 metabolic	 pathway	 is	 the	 tri-citric	 acid	 (TCA)	 cycle,	 also	
known	as	 the	Krebs	cycle	named	after	Hans	Krebs,	who	discovered	 it	 in	1957	 [87].	The	
TCA	cycle	takes	place	in	the	matrix	of	mitochondria	and	receives	products	from	multiple	
nutrients.	 Acetyl-CoA	 from	 glucose-derived	 pyruvate	 or	 fatty	 acids	 and	α-ketoglutarate	
from	glutamate	metabolism	enter	 the	cycle	at	different	 stages.	 In	a	 series	of	 reactions,	
the	 TCA	 cycle	 yields	 NADH	 and	 FADH2	 that	 transfer	 their	 electrons	 to	 the	 ETC	 for	 the	
generation	of	ATP	during	OXPHOS	(reviewed	in	Figure	2).	
The	TCA	cycle,	along	with	the	ETC	and	OXPHOS,	is	a	highly	efficient	energy	pathway	that	
is	 predominantly	 performed	by	 cells	 that	 are	quiescent	 or	 non-proliferating	 and	whose	
main	requirement	is	longevity	[76].	However,	if	specific	growth	signals	are	present,	they	
can	promote	the	production	of	amino	acid	and	lipids	from	TCA	cycle	intermediates.	This	
modification	 of	 TCA	 cycle	 reactions	 requires	 nutrient	 abundance	 and	 diversion	 to	 the	







from	the	glycolytic	pathway	 (Figure	2)	 for	 the	production	of	nucleotide	and	amino	acid	
precursors	 (e.g.	 for	DNA	and	RNA	 synthesis)	 as	well	 as	NADPH	 (phosphorylated	NADH)	




Amino	 acids	 are	 essential	 building	 blocks	 for	 protein	 synthesis	 associated	with	 the	 PPP	
and	 are	 used	 as	 substrates	 in	 different	 metabolic	 reactions,	 e.g.	 FAS.	 The	 amino	 acid	
Glutamine	 can	 be	 taken	 up	 by	 the	 cell,	 converted	 to	 glutamate	 and	 finally	 α-




Taken	 together,	 the	 cellular	 energy	 metabolism	 pathways	 comprehensively	 described	










processes.	 An	 activated	 immune	 cell	 requires	 an	 increased	 energy	 production	 with	





for	 energy	 production,	 increased	 TCA	 cycle	 activity,	 glutaminolysis	 as	 well	 anabolic	
processes	 including	 the	 PPP.	 These	 mechanisms	 of	 increased	 energy	 pathways	 in	
activated	cells	are	observed	in	adaptive	immune	cells	 like	T	cell	and	B	cells	as	well	as	 in	
innate	 immune	 cells	 like	macrophages	 or	 NK	 cells	 [63],[76].	 Depending	 on	 the	 kind	 of	
energy	metabolism	the	cell	relies	on,	it	is	able	to	perform	specific	functions.	Without	the	
switch	 to	 an	 elevated	 energy	 metabolism,	 an	 immune	 cell	 could	 not	 implement	 pro-
inflammatory	signaling.	
Figure	4	 shows	a	brief	overview	of	 resting	and	active	 state	T	cell	 characteristics.	T	 cells	
that	 are	 in	 a	 more	 resting	 state	 include	 naïve	 T	 cells,	 memory	 T	 cells	 and	 resting	
regulatory	T	cells.	These	cell	populations	are	in	a	metabolically	latent	state	and	switch	to	
increased	 immunometabolism	 once	 they	 become	 activated	 [88].	 This	 increase	 in	
metabolic	 function	 is	 crucial	 for	 CD4+	 helper	 T	 cell,	 CD8+	 effector	 T	 cell	 and	 activated	
regulatory	 T	 cell	 function	 [73],[74]	 and	 allows	 memory	 T	 cells	 to	 undergo	 clonal	
expansion.	 Along	 with	 elevated	 immunometabolism,	 particularly	 glycolytic	 activity,	
intracellular	and	extracellular	pH	levels	increase	due	to	elevated	lactate	and	CO2	secretion	






















as	 well	 as	 the	 key	 metabolic	 regulators	 of	 CD4+	 T	 cell	 subtypes	 essential	 for	 the	
preservation	of	the	cell	type.	Key	metabolic	signaling	molecules	in	pro-inflammatory	T	cell	
activation	include	mTOR	(mammalian	target	of	rapamycin),	the	hormone	receptor	ERRα	
(estrogen	 receptor	α)	 and	 the	 transcription	 factor	HIF-1α	 (hypoxia-inducible	 factor-1α)	
(helper	 T	 cell	 subpopulations).	 AMPK	 (AMP-activated	 protein	 kinase)	 acts	 in	 immune-
suppressive	 and	 anti-inflammatory	 signaling	 pathways.	 These	metabolic	 regulators	 play	











OXPHOS:	oxidative	phosphorylation,	FAS:	 fatty	acid	 synthesis,	FAO:	 fatty	acid	oxidation,	
AA	 met.:	 Amino	 Acid	 metabolism,	 Th:	 helper	 T	 cell,	 mTOR:	 mechanistic	 target	 of	
rapamycin,	ERR:	estrogen	receptor,	HIF-1α:	hypoxia-inducible	factor-1α,	FoxP3:	forkhead	
P3,	 AMPK:	 AMP-activated	 protein	 kinase,	 TN:	 naïve	 T	 cell,	 CM:	 central	 memory,	 EM:	
effector	memory,	 TEMAR:	 terminally	 differentiated	effector	memory	 cells	 re-expressing	
CD45RA.	
Just	 like	 CD4+	 T	 cell	 subsets,	 CD8+	 T	 cells	 rely	 on	 adaptations	 in	 energy	 metabolic	
pathways	and	show	comparable	metabolic	profiles.	Naïve	CD8+	T	cells	predominantly	use	
OXPHOS	and	glycolysis	to	meet	their	energy	demand	[89].	The	high	active	state	of	CD8+	














Taken	 together,	 immune	cells	are	 in	 constant	exchange	with	 their	metabolic	 regulatory	
systems	 in	 order	 to	 respond	 to	 the	 cellular	 requirements	 and	 defend	 the	 host	 against	
intruding	pathogenic	agents.	




Importantly,	 the	 interplay	of	physiological	and	psychological	 stress	 response	systems	as	
well	as	exhaustion	of	T	cells	due	to	prolonged	stimulation	and	activation	are	key	factors	
contributing	 to	 the	 pathology	 and	 symptoms	 of	 MS	 and	 have	 to	 be	 taken	 into	
consideration	when	discussing	the	essential	interplay	of	metabolism	in	MS	disease.		
1.3.3 HPA-axis	Stress	Response	Signaling		
One	 of	 the	 main	 stress	 response	 systems	 in	 the	 human	 body	 is	 the	 hypothalamus-
pituitary-adrenal	 (HPA)	 axis,	 which	 involves	 a	 cascade	 of	 mechanisms	 of	 hormone	
secretion	by	tissues	of	the	brain	and	kidney.		
The	 HPA	 axis	 is	 activated	 upon	 an	 encounter	 of	 an	 individual	 with	 a	 physiological	 or	
psychological	 stressor.	 It	 commences	 with	 the	 secretion	 of	 corticotropin-releasing	
hormone	 (CRH)	 by	 neuroendocrine	 neurons	 of	 the	 hypothalamus.	 Secondly,	 CRH	




pituitary	 gland.	 Lastly,	 ACTH	 acts	 on	 the	 adrenal	 cortex	 of	 the	 adrenal	 gland	 inducing	
glucocorticoid	 (GC)	 synthesis.	 The	 adrenal	 gland	 predominantly	 secrets	 the	GC	 cortisol,	
which,	 in	 a	 negative	 feedback	 loop,	 has	 the	 potential	 to	 act	 on	 the	 hypothalamus	 and	
pituitary	gland	preventing	CRH	and	ACTH	secretion.	For	clinical	analysis,	cortisol	levels	are	
mainly	measured	in	saliva	samples	from	individuals.	
GCs	 are	 one	 of	 the	 most	 potent	 hormones	 modulating	 pro-	 and	 anti-inflammatory	
processes	 in	 the	body	and	bind	 the	glucocorticoid	and	mineralocorticoid	 receptors.	The	
glucocorticoid	 receptor	 (GR)	 is	 found	 in	 the	 cytosol	 of	 various	 body	 cells	 including	
neurons	 and	 immune	 cells.	 In	 immune	 cells,	 GCs	 induce	 anti-inflammatory	 signaling	
pathways	 and	with	 that	 immunosuppression	 either	 by	 direct	 binding	 to	 proteins	 or	 by	
regulating	 gene	 expression	 of	 specific	 targets	 [95].	 One	 of	 the	 major	 mediators	 of	
immunosuppression	via	GCs	 is	 the	anti-inflammatory	protein	GC-induced	 leucine	 zipper	
(GILZ),	which	binds	 and	 inhibits	 one	of	 the	main	 pro-inflammatory	 signaling	molecules,	
NFκB	[96],[97].	The	comprehensive	mechanisms	by	which	GCs	induce	anti-inflammatory	
actions	in	cell	signaling	pathways	are	reviewed	extensively	by	Libert	and	Dejager	[98].		
In	 healthy	 individuals,	 the	 process	 of	 cortisol	 release	 and	 GC	 signaling	 allows	 the	
suppression	of	 immune	responses	 in	 favor	of	 the	activation	of	 the	sympathetic	nervous	
system	 and	 the	 physiological	 and	 psychological	 stress	 response.	 Once	 the	 stressor	 is	
absent,	cortisol	levels	decrease.	During	the	day,	cortisol	levels	peak	in	the	morning	before	
awakening	 and	 decrease	 over	 the	 course	 of	 the	 day	 with	 the	 lowest	 levels	 at	 night	
initiating	sleep.		
In	 autoimmune	 patients,	 alterations	 in	 HPA	 axis	 activity	 in	 combination	with	 increased	





mechanisms	 and	metabolic	 functionality	 [100].	 Furthermore,	 the	prolonged	 stimulation	
and	activation	of	T	cells	is	associated	with	cellular	exhaustion	mechanisms,	which	can	be	
driven	forward	by	systemically	altered	stress	response	systems.		







months.	 It	coincides	with	the	expression	of	specific	 inhibitory	cell	 surface	receptors,	 for	
example	cytotoxic	T	lymphocyte	associated	protein	4	(CTLA-4),	T	cell	immunoglobulin	and	
mucin	 domain	 containing	 protein	 3	 (TIM-3),	 B	 and	 T	 lymphocyte	 attenuator	 (BTLA),	
lymphocyte	activation	gene	3	 (LAG-3)	or	programmed	cell	death-1	 (PD-1)	 [101],[102].	T	
cell	 exhaustion	 can	 be	 induced	 during	 or	 after	 chronic	 infections	 and	 cancer	 involving	
persistent	 and	 ongoing	 antigen	 exposure	 and	 overall	 inflammation.	 The	 state	 of	 T	 cell	
exhaustion	prevents	the	induction	of	an	optimal	immune	response	to	infection	or	tumor.	
However,	this	state	has	been	shown	to	be	reversible	and	immune	re-activation	possible,	if	




of	 chronic	 infections,	 the	potential	of	driving	epitope	mutation	 in	 chronic	 infections,	or	
the	 prevention	 of	 tissue	 damage.	 Overall,	 from	 an	 evolutionary	 standpoint,	 a	 host-
pathogen	 balance	 is	 established	 in	 persisting	 infections	 allowing	 immune	 control	 and	
preventing	 uncontrolled	 pathogen	 replication.	 Importantly,	 inhibitory	 cell	 surface	
receptors	 are	 crucial	 regulators	 or	 auto-reactivity	 and	 are	 essential	 in	 preventing	
autoimmunity	[106].	












processes.	 Activated	 immune	 cells	 require	 altered	 metabolic	 pathways	 and	 signaling	




of	 immune	cells	 from	MS	patients,	especially	of	T	 cell	 subtypes,	need	 to	be	 considered	




by	 immunization	 with	 myelin-specific	 antigen	 and	 adjuvants	 [107],[108].	 EAE	 presents	
with	 complex	 immunopathological	 and	 neuropathological	 conditions	 that	 have	 been	
shown	 to	 be	 comparable	 to	 the	 key	 pathological	 symptoms	 observed	 in	 MS,	 namely	
systemic	 inflammation	 and	 CNS	 neuronal	 demyelination	 [108].	 In	 the	 murine	 model,	
several	factors	benefiting	a	positive	course	of	disease	and	decline	of	symptoms	as	well	as	
complete	 reduction	 of	 EAE	 disease	 have	 been	 observed.	 For	 example,	 fasting	 (no	 food	
intake	for	up	to	16	hours)	and	ketogenic	diet	(strong	reduction	of	carbohydrates	in	diet)	




benefit	 the	 disease	 course	 [110].	 A	 comprehensive	 review	 describing	 the	 link	 between	
metabolism	 and	 immune	 function	 including	 cytokine	 and	 hormone	 effects	 by	 specific	
innate	and	adaptive	 immune	cells	was	 recently	published	by	Alwarawrah	et.	 al	 in	2018	
[111].	 The	 authors	 describe	 in	 detail	 that	 impaired	metabolic	 signaling	 interplays	 with	
immune	 function,	 is	 linked	 to	 autoimmunity	 and	 possesses	 potentials	 for	 therapy	 in	
autoimmune	 diseases.	 Furthermore,	 the	 positive	 effects	 of	 autophagy	 in	 inflammatory	
processes	 and	 auto-immunity	 have	 been	 described	 [112].	 Autophagy	 is	 defined	 as	 an	
evolutionary	 conserved	 process	 of	 cellular	 self-renewal	 by	 lysosomal	 degradation	 of	
macromolecules	 thereby	 eliminating	 waste	 products	 and	 maintaining	 the	 metabolic	






that	 indicating	 the	 potential	 for	 reestablishing	 impaired	 metabolic	 balance	 in	 immune	
cells	[116]–[119].	
To	date,	there	are	few	studies	on	the	mechanisms	of	immunometabolism	in	MS	disease	in	
humans.	 Impairments	 in	 mitochondrial	 respiration	 and	 glycolytic	 activity	 has	 been	
observed	in	PBMCs	from	MS	patients	[120].	In	2015,	De	Riccardis	and	colleagues	showed	
impairments	in	CD4+	T	cells	from	RRMS	patients	with	decreased	mitochondrial	respiration	
and	 increased	 glycolytic	 activity	 [121].	 These	 studies	 provide	 first	 insights	 into	 human	




binds	 to	 the	 GR	 of	 immune	 cells	 and	 induces	 decreased	 pro-inflammatory	 signaling	
cascades.	Importantly,	in	immune	cells,	the	frequent	induction	of	the	GR	can	lead	to	the	
down-regulation	 of	 the	 receptor	 by	 the	 cell.	 Thereby,	 the	 cell	 possesses	 the	 ability	 to	
escape	 the	 induction	 of	 anti-inflammatory	 signaling	 via	 the	 HPA	 axis	 and	 cortisol	
hormone.	In	MS	patients,	alterations	in	HPA	axis	activity	have	been	shown,	including	the	
down-regulation	of	 the	GR	and	associated	proteins	 [122].	Alterations	 in	stress	 response	
systems	 and	 pro-inflammatory	 signaling	 in	 immune	 cells	 impact	 cellular	 energy	
metabolism	and	should	therefore	be	considered	in	autoimmunity.	
These	 first	 studies	 in	 murine	 models	 and	 MS	 patients	 strongly	 allude	 to	 overall	
impairments	in	immunometabolic	cell	signaling	and	energy	transduction	pathways.	They	
provide	firm	data	for	future	analyses	of	metabolic	dysfunctions	in	MS	disease.		
Particularly,	 mitochondrial	 function	 in	 T	 cells	 of	 MS	 patients	 in	 the	 context	 on	 pro-
inflammatory	cell	signaling	needs	to	be	studied	and	its	potential	for	therapeutic	targets.	














Figure	 5:	 Model	 of	 Immunometabolic	 Signaling.	 The	 model	 includes	 three	 aims	 that	 were	
analyzed	as	part	of	this	dissertation.	Aim	1:	energy	metabolic	analyses	using	the	Seahorse	96eXF	
Analyzer	 and	 mitochondrial	 stress	 test	 kit.	 Aim	 2:	 gene	 expression	 mRNA	 analysis	 of	 CPT1a,	
GLUT1,	NFκB1,	NF-κB3,	TNFα,	GR,	GILZ.	Aim	3:	flow	cytometry	analyses	of	chemokine	receptors	
as	 well	 as	 PD-1	 and	 CPT1a.	 Molecules	 in	 red	 show	 glycolysis-inducing	 signaling,	 molecules	 in	
orange	 demonstrate	 an	 induction	 in	 mitochondrial	 respiration.	 AKT:	 protein	 kinase	 B,	 AMPK:	
AMP-activated	protein	kinase,	CPT1a:	Carnitine	palmitoyltransferase	I	isoform	a,	CCR:	chemokine	
receptor,	 CD:	 cluster	 of	 differentiation,	 ETC:	 electron	 transport	 chain,	 FA:	 fatty	 acid,	 GLUT1:	
glucose	transporter	1,	NF-κB:	nuclear	factor	'kappa-light-chain-enhancer'	of	activated	B-cells,	PD-
1:	 programmed	 cell	 death-1,	 TCA:	 Tri-citric	 acid,	 TCR:	 T	 cell	 receptor,	 TNF-α:	 tumor	 necrosis	
factor-α.	
First,	mitochondrial	respiration	and	glycolytic	function	in	these	three	subpopulations	was	
assessed	using	 the	 Seahorse	 XFe96	Analyzer	 providing	 information	 about	mitochondrial	
activity.	 Secondly,	 qRT-PCR	 gene	 expression	 analyses	 provided	 information	 about	 key	




third	 aim,	 flow	 cytometry	 analyses	 provided	 data	 on	 the	 PBMC	 phenotype	 make-up	
(chemokine	 receptor	 analyses),	 extracellular	 PD-1	 T	 cell	 exhaustion	 surface	 marker	
analyses	as	well	as	intracellular	mitochondrial	membrane	protein	CPT1a	analyses.		
These	three	aims	link	mitochondrial	and	glycolytic	activity	to	gene	and	protein	expression	





Depression	 and	 Immune	 Function	 (DENIM)	was	 initiated	 and	 conducted	 as	 part	 of	 this	
dissertation.	 PBMCs	 were	 prepared	 for	 analyses	 and	 case	 report	 form	 assessments	
provided	information	about	RRMS	disease	parameters	as	well	as	additional	physiological	
and	psychological	 disease	 indications.	 Furthermore,	 saliva	 samples	 from	RRMS	patients	









As	 described	 in	 1.1,	 Multiple	 Sclerosis	 (MS)	 is	 a	 neurodegenerative	 disease	 strongly	
associated	with	auto-reactive	immune	cell	activation.	The	main	symptoms	of	MS	include	
motor	 deficits,	 cognitive	 impairments,	 decreased	 ability	 to	 focus	 and	 concentrate,	
depression	as	well	as	an	overall	inflammatory	phenotype.		
The	aim	of	the	clinical	study	Depression	and	Immune	Function	(DENIM)	was	to	gain	first	
insights	 into	 the	 underlying	 biological	 mechanisms	 of	 immune	 cell	 activation	 and	
neuropsychiatric	symptoms	in	patients	diagnosed	with	RRMS	with	and	without	comorbid	
major	 depressive	 disorder	 (MDD).	 The	 main	 interest	 was	 the	 analysis	 of	





Berlin	 on	May	 21st	 2015	 (application	 number:	 EA1/096/15).	 Data	 protection	 of	 patient	
and	healthy	control	(HC)	participant	information	is	guaranteed	based	on	the	Charité	Data	
Protection	 Statement.	 The	 study	 is	 listed	 on	 www.clinicaltrials.gov	 with	 the	 ID:	
NCT02740296.		
All	MS	patients	were	assessed	at	the	Neuro	Cure	Clinical	Research	Center	(NCRC)	(head:	
Prof.	 Dr.	 med.	 Friedemann	 Paul)	 at	 the	 Charité	 Campus	 Mitte,	 Berlin.	 HC	 participants	
were	assessed	at	the	NCRC	as	well	as	at	the	Department	of	Psychiatry	and	Psychotherapy,	







participants	 came	 into	 the	 clinic	 for	 the	 assessment,	 which	 included	 a	 blood	 draw,	
analysis	of	vital	parameters,	cognitive	tests,	demographic,	psychological	and	physiological	
health	 questionnaires	 and	 a	 structured	 clinical	 interview	 assessing	 the	 psychological	
health.	 Furthermore,	 all	 patients	 and	 participants	 took	 saliva	 samples	 in	 the	 two	 days	
following	the	study	visit.	The	visit	was	scheduled	between	8	am	and	10	am.	Patients	and	
participants	 came	 in	 for	 a	 fasting	 blood	draw	after	 not	 having	 eaten	 for	 12	 hours.	 The	
study	 was	 conducted	 in	 German	 and	 all	 questionnaires	 were	 in	 German.	 Patients	 and	
participants	were	all	native	German	speakers	or	had	language	levels	of	a	native	speaker.	
An	overview	of	all	 study	visit	assessments	 is	given	 in	Table	5	and	complete	case	 report	
form,	telephone	screening	sheets	and	salivary	sample	collection	sheets	in	Appendix.		
2.1.2.3 Inclusion	and	Exclusion	Criteria	




diagnosis	 of	 RRMS	 and	 a	 current	 diagnosis	 of	 MDD	 (cohort	 RRMS+MDD),	 3)	 patients	
suffering	 from	MDD	 and	 no	 commodities	 of	 the	 immune	 system	 (cohort	MDD)	 and	 4)	
healthy	control	participants	(cohort	HC).	For	this	dissertation,	the	cohorts	RRMS	and	HC	
were	recruited	and	analyzed	and	information	given	here	are	related	to	these	two	cohorts.	









Table	 4:	 Inclusion	 and	 exclusion	 criteria	 of	 the	 clinical	 study	 Depression	 and	 Immune	
System	for	RRMS	patients	and	healthy	control	participants.	
Inclusion	criteria	 Exclusion	criteria	
• confirmed	 diagnosis	 of	 RRMS;	 no	
immune	modulatory	 therapy	 or	 stable	
immune	 modulatory	 therapy	 for	 at	
least	6	months		
• Infection	within	the	past	2	months	(e.g.	
the	 flu,	 a	 cold,	 a	 stomach	 virus	
infection)	
• Between	18	and	55	years	of	age	 • Pregnancy	
• BMI	≤	30	 • Epilepsy,	 Schizophrenia	 or	 other	
neurological	or	psychiatric	diseases	
• No	 steroid	 treatment	 for	 the	 past	 3	
months	
• Rheumatism,	 Lupus	 or	 any	 other	
immune	diseases	
• No	vaccination	in	the	past	3	months	 • Diabetes	
• Fasting	 blood	 draw	 after	 not	 having	
eaten	for	12	hours	
• HIV	or	Hepatitis	infection	




• Treatment	 with	 any	 of	 these	 drugs:	
anti-psychotics,	 antidepressants,	
insulin,	anti-epileptic	medicines	
• Medicines,	 alcohol	 or	 drug	 abuse	
within	the	past	year	
• Participant	in	an	interventional	study	
HC:	 Healthy	 Control,	 RRMS:	 Relapsing	 Remitting	 Multiple	 Sclerosis,	 BMI:	 Body	 Mass	
Index,	HIV:	Human	Immunodeficiency	Virus.	
2.1.2.4 Telephone	Screening	for	Study	Eligibility		






Case	 Report	 Forms	 (CRF)	 were	 conceptualized	 based	 on	 the	 study	 aims	 as	 well	 as	
































For	 routine	 blood	 analyses,	 whole	 blood	 samples	 were	 analyzed	 by	 a	 routine	 blood	
diagnostic	 laboratory	 (Labor	 Berlin,	 Berlin).	 A	 summary	 of	 items	 analyzed	 is	 given	 in	





Peripheral	 Blood	 Mononuclear	 Cells	 ).	 Saliva	 samples	 for	 cortisol	 analyses	 were	
completed	by	the	MS	patients	and	HC	participants	independently	at	home	after	given	the	






During	 the	 recruitment	 time,	 a	 total	 of	 52	 study	 visits	 for	 RRMS	patients	 and	 50	 study	
visits	 of	HC	 participants	were	 performed.	 	Of	 these,	 14	 RRMS	patients	were	 ‘drop-out’	




Generally,	 about	80	mL	of	 fresh	whole	blood	was	drawn	 from	each	MS	patient	and	HC	
participant	and	between	8x107	and	12x107	Peripheral	Blood	Mononuclear	Cells	(PBMCs)	
could	 be	 isolated.	 Aliquots	 of	 1x107	 cells/cryo	 tube	 were	 frozen	 and	 stored	 in	 liquid	
nitrogen.	Saliva	samples	of	MS	patients	and	HC	participants	were	prepared	and	stored	at		
-20°C	until	analysis.		
All	 CRF	 data	 were	 computerized	 and	 statistics	 were	 performed	 using	 SPSS	 (IBM).	




























































































































































The	CPT1a	gene	probe	binds	 five	different	 reference	sequences	 [123]	 including	the	one	
detected	by	the	flow	cytometry	CPT1a	antibody.	For	NFκB	expression	analysis,	two	subunits	





















A	 full	 list	 of	 antibodies	 used	 for	 magnetically	 activated	 cell	 sorting	 (MACS)	 and	 flow	
cytometry	analyses	is	provided	in	Table	11	and	Table	12	respectively.	
Table	 11:	 List	 of	 antibodies	 used	 for	Magnetically	 Activated	 Cell	 Sorting	 (MACS)	 and	
flow	cytometry.	
MACS	antibodies	 	
antigen	 linked	to	 						clone	 concentration	 company	
CD4	 	Micro	beads	 							n/a	 									1:5	 Miltenyi,	Biotech	
GmbH,	Bergisch	
Gladbach	CD8	 	Micro	beads	 							n/a	 									1:5	
Flow	cytometry	analysis	antibodies	
antigen	 linked	to	 clone	 concen
tration	
company	
CPT1a	 AlexaFluor®488	 8F6AE9	 1:100	 Abcam,	Cambridge,	UK	
IgG2b	 AlexaFluor®488	 7E10G10	 1:100	 Abcam,	Cambridge,	UK	
CD279	(PD-1)	 PE	 EH12.2H7	 1:40	 Biotechne,	Wiesbaden	
CD127	(IL-7Rα)	 APC	 A019D5	 1:50	 Biolegend,	London,	UK	
CD16	 APC	 3G8	 1:500	 Biolegend,	London,	UK	
CD194	(CCR4)	 APC	 L291H4	 1:25	 Biolegend,	London,	UK	
CD197	(CCR7)		 APC	 G043H7	 1:20	 Biolegend,	London,	UK	
CD14	 Brilliant	Violet	421™	 HCD14	 1:500	 Biolegend,	London,	UK	
CD183	(CXCR3)	 Brilliant	Violet	421™	 G025H7	 1:100	 Biolegend,	London,	UK	
CD25	(IL-2Rα)	 Brilliant	Violet	421™	 M-A251	 1:100	 Biolegend,	London,	UK	
CD3	 Brilliant	Violet	421™	 UCHT1	 1:200	 Biolegend,	London,	UK	
CD3	 Brilliant	Violet	510™	 UCHT1	 1:25	 Biolegend,	London,	UK	
CD8a	 Brilliant	Violet	510™	 RPA-T8	 1:25	 Biolegend,	London,	UK	
CD196	(CCR6)	 PE/Cy7	 G034E3	 1:50	 Biolegend,	London,	UK	
CD20	 PE/Cy7	 2H7	 1:500	 Biolegend,	London,	UK	
CD45RA	 PE/Cy7	 HI100	 1:200	 Biolegend,	London,	UK	
CD4	 PerCP/Cy5.5	 PRA-T4	 1:50	 Biolegend,	London,	UK	























































































saline)	 (room	 temperature	 (RT))	 and	 carefully	 layered	 on	 top	 of	 15	 mL	 of	 Biocoll	
Separating	Solution	(Merck,	Biochrom)	(RT).	This	preparation	was	centrifuged	for	30	min	
(RT)	at	300xg	with	the	centrifuge	break	off.	The	PBMC	monolayer	was	distracted	from	the	
separated	blood	contents	and	washed	 two	 times	 in	1xPBS	 (4°C).	PBMCs	were	added	 to	
RPMI	1640	GlutaMAX™	medium	(GIBCO,	Life	Technologies)	supplemented	with	25%	FCS	
(Merck,	Biochrome)	and	10%	DMSO	(AppliChem	GmbH).	Aliquots	of	1x107	cells/cryo	tube	
were	 slowly	 frozen	 to	 -80°C	 at	 10°C	 per	 hour	 intervals	 in	 a	 Mr.	 Frosty	 container	
(Nalgene®).	After	20-30	hours,	 the	 frozen	aliquots	were	 transferred	 into	 liquid	nitrogen	
for	long	time	storage.	
2.3.1.2 Thawing	of	PBMCs	
PBMCs	 in	cryo	tubes	were	taken	out	of	the	 liquid	nitrogen	container	and	placed	on	 ice.	
Cells	were	thawed	quickly	to	37°C	and	subsequently	resuspended	in	45	mL	of	37°C	RPMI	
medium	with	 GlutaMAX™	 supplemented	with	 10%	 FCS	 and	 centrifuged	 at	 300xg	 for	 5	











supernatant	 was	 taken	 off	 and	 80	 µL	 of	 MACS	 buffer	 and	 20	 µL	 CD4	 positive	 T	 cell	
selection	MACS	antibody	(Miltenyi)	were	added	per	5x106	cells.	The	cell	suspension	was	




suspension	 was	 applied	 onto	 the	 column.	 Here,	 the	 magnetically	 labeled	 CD4+	 T	 cells	
were	 retained	 inside	 the	 column	 and	 the	 non-labeled	 cells	 (negative	 fraction)	 were	
washed	 out	 into	 a	 15	 mL	 falcon	 tube.	 To	 retrieve	 the	 magnetically	 labeled	 cells,	 the	
column	was	placed	outside	the	magnet	 into	a	new	15	mL	falcon	tube	and	rinsed	with	5	
mL	MACS	buffer.	The	cells	were	centrifuged	at	300xg	for	5	min.	and	the	supernatant	was	
taken	 off.	 Following	 the	 CD4+	 T	 cell	 selection,	 CD8+	 T	 cells	 were	 separated	 from	 the	
negative	fraction	using	the	same	protocol	and	the	CD8	positive	selection	MACS	antibody	
(both	Miltenyi).		
Subsequently,	 three	 fractions	were	 obtained:	 CD4+	 T	 cells,	 CD8+	 T	 cells	 and	 a	 negative	














In	 order	 to	 contribute	 valid	 data,	 the	 Mitochondrial	 Stress	 Test	 Analyses	 using	 the	
Seahorse	 XFe	 96	 analyzer	 had	 to	 be	 established	 for	 human	 immune	 cell	 bioenergetic	
analyses.	According	to	the	manufacturer’s	instructions	(Agilent),	the	following	tests	were	
performed:	 titration	 of	 optimal	 FCCP,	 oligomycin	 and	 rotenone	 with	 antimycin	 A	
concentrations	as	well	as	the	required	cell	number	per	well.	The	following	concentrations	
were	determined	as	optimal	based	on	the	pre-analyses	assays:	FCCP:	2	µM,	oligomycin	1	
µM,	 rotenone	 with	 antimycine	 A:	 0.5	 µM.	 The	 cryopreserved	 PBMCs	 from	 a	 healthy	
donor	 were	 thawed	 10	 days	 after	 blood	 draw	 for	 the	 assay	 analysis	 (see	 2.3.1	 for	
methods).	Cell	density	 tests	 revealed	4x105	 cells/well	 giving	optimal	OCR	values	 (Figure	
6).	Data	was	analyzed	using	the	manufacturer’s	provided	Mito	Stress	Test	Kit	Generator	





Figure	 6:	 Seahorse	 XFe	 96	 Analyzer	 assay	 test	 analyses	 for	 cell	 density	 determination	 shows	




Antimycin	 A	 using	 a	 Seahorse	 XFe	 96	 Analyzer	 (Agilent).	 Three	 different	 cell	 densities	 were	
analyzed:	 2x105	 cells/well,	 3x105	 cells/well	 and	 4x105	 cells/well.	 Mean	 and	 SEM	 calculated	 per	































are	 non-adherent,	 therefore,	 it	 was	 tested	 whether	 the	 cells	 are	 detaching	 from	 the	
culture	plate	during	mixing	times	in	the	Seahorse	analyzer.	This	would	lead	to	inaccurate	
readouts,	because	energy	consumption	of	detaching	cells	 floating	 in	the	medium	would	



















Figure	 7:	 Seahorse	 XFe	 96	 Analyzer	 metabolic	 assay	 cellular	 adherence	 testing	 shows	 no	
difference	 in	 OCR	 measurements	 with	 or	 without	 PDL	 plate	 coating.	 The	 graphs	 shows	
magnetically	purified	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	 (PBMCs	 lacking	CD4+	





D-Lysine,	 OCR:	 oxygen	 consumption	 rate,	 FCCP:	 Carbonyl	 cyanide-4-
(trifluoromethoxy)phenylhydrazone.									
	
Furthermore,	previous	 studies	of	Keane	et	al.	 [124]	 showed	 that	human	PBMCs	display	
decreasing	 bioenergetics	 over	 time	 in	 cryo-preservation.	 Keane	 and	 colleagues	 showed	
that	after	50	days	of	storage,	bioenergetic	levels	stabilized	and	did	not	decrease	further.	
To	 ensure	 equal	 treatment	 and	 exclusion	 of	 bioenergetic	 effects	 caused	 by	 freezing	










stimulated	 with	 1	 mg/mL	α-CD3	 (clone	 OKT)	 and	 1	 µg/mL	α-CD28	 (both	 eBioscience,	
ThermoFisher)	for	2	h,	22	h	or	left	unstimulated.	These	three	conditions	were	compared	
to	freshly	thawed	PBMCs.	It	was	observed,	that	freshly	thawed	and	analyzed	PBMCs	had	



















matched	HC	participants	 simultaneously	 at	 two	different	medical	 centers	within	 a	 time	














for	 two	 hours.	 Subsequently,	 the	 cells	 were	 harvested	 and	 washed	 with	 Seahorse	
Mitochondrial	Stress	Test	Kit	medium	(300xg,	5	min.).	The	cells	were	seeded	at	a	density	
of	 4x105	 cells	 per	 well	 into	 a	 Seahorse	 cell	 culture	 plate	 and	 incubated	 wrapped	 in	 a	
plastic	bag	at	37	°C	in	a	non-CO2	incubator	for	30	minutes.	The	sensor	cartridge	(Agilent	





D	 (all	 Agilent	 Technologies).	 All	 reagents	 were	 prepared	 with	 Seahorse	 Mitochondrial	
Stress	Test	Kit	medium.	To	prevent	vaporization	of	the	reagents	in	the	ports,	the	sensor	
cartridge	 was	 immediately	 placed	 into	 the	 analyzer	 for	 a	 15	min.	 calibration,	 which	 is	
required	by	the	machine	and	follows	the	company’s	instructions.	Finally,	the	cell	culture	
























The	Seahorse	XFe	96	Analyzer	measures	 the	changes	 in	oxygen	consumption	rate	 (OCR,	
pmols/min)	 and	 extracellular	 acidification	 rate	 (ECAR,	mpH/min)	 in	 the	medium	 under	
real-time	 conditions.	 Therefore,	 direct	 conclusions	 about	 mitochondrial	 aerobic	




in	 response	 to	 2)	 oligomycin,	 3)	 FCCP	 and	 4)	 rotenone	 and	 antimycin	 A.	 The	 values	
measured	by	the	Seahorse	XFe	96	Analyzer	were	analyzed	using	the	Wave	software	and	
Seahorse	 XFe	 96	 Mito	 Stress	 Test	 Generator	 V2	 (both	 Agilent,	 Waldbronn).	 OCR	
(pmoles/min.)	values	for	basal	respiration	(BR),	spare	respiratory	capacity	(SRC),	maximal	

























proton	 leak,	 ATP:	 adenosine	 triphosphate,	 SRC:	 spare	 respiratory	 capacity,	 ECAR:	
Extracellular	Acidification	Rate.	
	
Using	 the	 mitochondrial	 stress	 test	 assay	 for	 the	 Seahorse	 XFe	 96	 analyzer,	 basal	
extracellular	acidification	rate	(ECAR)	and	maximal	ECAR	after	oligomycin	injection	can	be	
evaluated	 (Table	 15).	 Changes	 in	mpH/min.	 after	 FCCP	 injection	 include	 changes	 in	 the	
medium	resulting	from	mitochondrial	respiration	and	other	bioenergetic	pathways	in	the	
cells	(e.g.	TCA	cycle,	pentose	phosphate	pathway),	which	influence	the	pH	of	the	medium.	
Therefore,	 only	 basal	 ECAR	 (last	 rate	 measurement	 before	 oligomycin	 injection)	 and	
maximal	ECAR	 (highest	value	after	oligomycin	 injection)	were	analyzed.	These	values	 in	
pH	changes	in	the	medium	provide	data	for	basal	cellular	glycolysis	rates	in	unstimulated	
cells	and	maximal	glycolysis	rates	during	mitochondrial	ETC	complex	V	inhibition.		
Due	 to	 differing	 outcomes	 in	 cell	 number	 from	 MS	 patients	 after	 density	 gradient	
centrifugation	 PBMC	 isolation	 and	 because	 of	 differences	 in	 cell	 viability	 potentially	
caused	by	MS	medication,	24	MS	patient-HC	participant	pairs	out	of	the	31	pairs	included	
in	the	study	analyses	(Table	16)	could	be	analyzed.		
The	 real-time	measurement	 of	 cell	 viability	 can	 cause	 readouts	 that	 can’t	 be	 used	 for	
analyses,	mainly	due	 to	cell	 viability	during	 the	assay	 run	or	possible	air	bubbles	 in	 the	




viability	 suffered	 or,	 by	 definition,	 CD8+	 T	 cell	 purification	 yielded	 lower	 outcome	 and	
could	not	be	analyzed,	the	data	was	excluded	resulting	in	the	differing	numbers	of	pairs	
analyzed	 (n-numbers).	 However,	 at	 least	 three	wells	 per	 cell	 population	were	 used	 for	
analyses	 in	 order	 to	 ensure	 data	 and	 statistical	 accuracy	 as	 well	 as	 to	 omit	 inter-well	
differences.	If	less	than	three	wells	were	analyzable,	the	data	was	excluded.	For	three	or	
more	 wells	 per	 cell	 population,	 the	 mean	 was	 calculated	 and	 used	 for	 data	 analyses.	
Exemplarily:	 for	MS	patients’	CD8+	T	cells	on	average	5.5	wells	 (mean,	SD	2.3)	could	be	
used	for	analyses.	For	HC	participants’	CD8+	T	cells	on	average	5.6	wells	 (mean,	SD	2.2)	
were	 used	 for	 analyses.	 There	 was	 no	 significant	 difference	 in	 the	 number	 of	 wells	




PBMCs	 from	 an	MS	 patient	 and	 correspondingly	 matched	 HC	 participant	 were	 always	
analyzed	in	parallel	 in	the	flow	cytometer.	The	cryo	preserved	PBMC	vials	used	were	all	
prepared	from	the	one	blood	draw	at	the	study	visit	(2.3.1),	which	ensures	comparability	
of	 the	results	between	the	different	experiments.	The	antibodies	are	 listed	 in	Table	11,	
the	corresponding	antibody	panels	used	are	listed	in		
Table	 12	 and	 Figure	 15	 give	 an	 overview	 of	 the	 final	 cell	 phenotypes	 analyzed.	 The	




for	 each	 panel.	 The	 tubes	 were	 incubated	 in	 the	 dark	 at	 RT	 for	 15	 minutes	 with	 the	
live/dead	marker	Zombie	NIR	 in	50	µL	1xPBS.	For	staining	panel	1	(Table	12),	the	CCR7-
APC	 antibody	was	 also	 added	 to	 the	 solution.	 Subsequently,	 50	 µL	 of	 the	 extracellular	





For	 intracellular	 staining,	 100	 µL	 cytofix/cytoperm	 (Becton	 Dickinson)	 were	 added	 and	
cells	 were	 incubated	 for	 15	 min.	 (RT,	 in	 the	 dark).	 The	 cells	 were	 washed	 in	 1	 mL	
perm/wash	(Becton	Dickinson)	(300xg,	5	min.).	Anti-CPT1a-AlexaFluor®488	was	diluted	in	
100	 µL	 perm/wash	 and	 incubated	with	 the	 cells	 for	 30	minutes	 at	 RT	 in	 the	 dark.	 For	
isotype	control	analyses,	the	corresponding	isotype	was	used.	The	cells	were	washed	in	1	







panels	 used	 (Table	 12).	 Figure	 9	 through	 Figure	 13	display	 the	 gating	 strategy	 for	 each	





























































































































determination	 of	 T	 cells	 was	 distinguished	 by	 CD4	 and	 CD8	 surface	 expression.	 T	 cell	 memory	
subsets	were	discriminated	based	on	CCR7	and	CD45RA	surface	expression:	TCM:	CCR7+	CD45RA-,	
naïve:	CCR7+	CD45RA+,	TEM:	CCR7-	CD45RA-,	TEMRA:	CCR7-	CD45RA+.	TCM:	central	memory	T	cell,	





HC	 participants.	 Cells	 were	 gated	 on	 single	 cell	 live	 lymphocytes	 as	 shown	 in	 Figure	 9:	
lymphocytes	 were	 identified	 based	 on	 size	 using	 forward	 scatter	 (FSC)	 and	 side	 scatter	 (SSC).	
Doublets	were	excluded	based	on	FSC-H	(height)	and	FSC-A	(area)	followed	by	dead	cell	exclusion.	









































































CD4+	 T	 cells.	 Flow	 cytometry	 analyses	 of	 cryopreserved	 PBMCs	 from	 MS	 patients	 and	 HC	
participants.	Cells	were	gated	on	single	cell	 live	 lymphocytes	as	shown	 in	Figure	9:	 lymphocytes	
were	 identified	based	on	 size	using	 forward	 scatter	 (FSC)	and	 side	 scatter	 (SSC).	Doublets	were	
excluded	based	on	 FSC-H	 (height)	 and	 FSC-A	 (area)	 followed	by	dead	 cell	 exclusion.	 T	 cells	 and	
non-T	cells	were	discriminated	based	on	CD3	surface	expression.	helper	T	cells	were	distinguished	






Flow	 cytometry	 analyses	 of	 cryopreserved	 PBMCs	 from	MS	 patients	 and	 HC	 participants.	 Cells	
were	 gated	 on	 single	 cell	 live	 lymphocytes	 as	 shown	 in	 Figure	 9:	 Lymphocytes	 were	 identified	
based	on	size	using	forward	scatter	(FSC)	and	side	scatter	(SSC).	Doublets	were	excluded	based	on	
FSC-H	 (height)	 and	 FSC-A	 (area)	 followed	 by	 dead	 cell	 exclusion.	 T	 cells	 and	 non-T	 cells	 were	










































Figure	 13:	 Gating	 strategy	 for	 panel	 4	 of	 phenotyping	 analyses	 to	 determine	 monocyte	
subpopulations.	 Flow	 cytometry	 analyses	 of	 cryopreserved	 PBMCs	 from	 MS	 patients	 and	 HC	
participants.	 Monocytes	 were	 identified	 based	 on	 forward	 scatter	 (FSC)	 and	 side	 scatter	 (SSC)	
properties.	Doublets	were	excluded	based	on	FSC-H	 (height)	and	FSC-A	 (area)	 followed	by	dead	
cell	 exclusion.	 T	 cells	 and	 non-T	 cells	 were	 discriminated	 based	 on	 CD3	 surface	 expression.	
Contaminating	B	cells	and	NK	cells	were	excluded	based	on	CD20	and	CD56	expression.	Monocyte	




to	 its	 isotype	 control.	 CD4+	 naïve	 T	 cells	 (full	 gating	 shown	 in	 Figure	 9)	 were	 set	 as	 a	
negative	 reference	 (Figure	 14	 B)	 to	 determine	 PD-1	 positive	 T	 cell	 populations.	 An	
















lymphocytes	 as	 shown	 in	 Figure	 9:	 lymphocytes	 were	 identified	 based	 on	 size	 using	 forward	
scatter	 (FSC)	and	side	scatter	 (SSC)	properties.	Doublets	were	excluded	based	on	FSC-H	(height)	
and	FSC-A	(area)	followed	by	dead	cell	exclusion.	T	cells	and	non-T	cells	were	discriminated	based	






(green).	 TEM:	 effector	 memory	 T	 cells,	 TN:	 naïve	 T	 cell,	 TCM:	 central	 memory	 T	 cell,	 TEMRA:	





































respective	 surface	 receptors	 to	 determine	 cell	 phenotypes.	 The	 figure	 illustrates	 the	 surface	
receptors	 used	 to	 differentiate	 cell	 populations.	 CCR:	 CC	 chemokine	 receptor,	 CXCR3:	 CXC	






cells	 from	 MS	 patients	 and	 healthy	 control	 participants,	 aliquots	 of	 these	 three	 cell	
fractions	were	taken	after	the	two	hour	resting	period	following	the	magnetic	cell	sorting	
(see	 2.3.1.3	 and	 2.3.1.4).	 The	 cells	 were	 centrifuged	 at	 300xg	 for	 5	 minutes	 and	 the	








Strand	 cDNA	 Synthesis	 Kit,	 ThermoFisher	 Scientific)	 were	 performed	 following	 the	
manufacturer’s	instructions.	RNA	measurements	were	performed	on	a	NanoDrop™2000c	
Spectralphotometer	(ThermoFisher,	Life	Technologies).	For	each	cell	fraction	from	an	MS	














analyzed	 in	 triplicates	 with	 two	 housekeeping	 genes	 (TATA	 Box	 Binding	 Protein	 and	
Importin	8)	analyzed	for	reference.	Following	2	minutes	at	50	°C	and	10	minutes	at	95°C,	
40	cycles	were	performed	as	follows:	15	seconds	at	95°C,	1	minute	at	60°C.	Finally,	4°C	to	












Cortisol	 detection	 ELISA	 kit	 (IBL)	 according	 the	manufacturer’s	 instructions.	MS	 patient	
and	HC	participant	sample	pairs	were	analyzed	on	the	same	plate.	
2.3.6 Statistical	Analyses	










correlation	 test	 was	 used.	 This	 test	 also	 does	 not	 require	 normal	 distribution	 of	 data.				
The	Spearman’s	rank	correlation	coefficient	rS	indicates	the	power	and	direction	(positive	
or	negative	correlation)	of	linear	statistical	association,	providing	values	between	-1	and	









including	 the	 state	 of	 activation,	 senescence,	 differentiation,	 memory	 development	 or	
proliferation	 [129].	 	 Immune	 cells	 respond	 to	 external	 environmental	 factors	 in	 their	
immediate	 microenvironment	 and	 induce	 energy	 metabolic	 shifts	 from	 inside	 the	 cell.	
The	 immune	 system	 of	 patients	 diagnosed	 with	 RRMS	 is	 continuously	 triggered	 and	
repeatedly	activated.	This	chronic	immune	activation	may	induce	shifts	in	normal	immune	




MS	patients	and	HC	participants	were	 recruited	as	part	on	 the	Depression	and	 Immune	
System	(DENIM)	study	 (see	2.1	 for	 full	 information	regarding	recruitment	and	Appendix	
for	 full	 Case	Report	 Form).	Main	 characteristics	of	MS	patients	 and	HC	participants	 are	
displayed	 in	Table	16.	Patients	and	controls	were	 thoroughly	matched	 for	 sex,	age	 (±	5	
years),	BMI	(±	2	kg/m2)	and	current	smoking	status.	Due	to	careful	matching	of	patients	









216].	 Depression	 scores	 of	 MS	 patients	 and	 HC	 participants	 were	 rated	 in	 a	 clinical	




cohorts	 did	 not	 meet	 MDD	 criteria	 (Table	 16).	 The	 BDI-II	 and	 BAI	 are	 self-rated	
questionnaires.	MS	patients	showed	significantly	higher	BDI-II	 (p<0.01)	and	BAI	(p=0.02)	
scores	 compared	 to	HC	participants.	However,	 in	both	groups,	 the	 scores	did	not	meet	
depression	 or	 anxiety	 disorder	 criteria.	 Cognitive	 ability	 testing	 using	 the	 Single	 Digit	
Modality	 Scale	 (SDMT)	 [134]	 did	 not	 reveal	 differences	 between	 MS	 patients	 and	 HC	
participants	 (p=0.13).	 The	 Expanded	 Disability	 Status	 Scale	 (EDSS)	 [135]	 testing	 was	
performed	with	MS	patients	 to	 rate	 the	patient’s	disability	status	 ranging	 from	0	to	10.	
The	MS	patient	cohort	had	a	median	EDSS	of	2	with	results	ranging	from	0	to	4.5	within	
the	cohort.		
Blood	pressure	measurements	revealed	normal	ranges	 in	both	cohorts	and	 levels	 for	C-
reactive	protein	(CRP)	did	not	indicate	inflammation	(Table	16).		
In	conclusion,	MS	patients	and	HC	participants	did	not	show	any	concomitant	psychiatric	
disorders	 or	 indicators	 for	 pro-inflammation	 induced	 by	 concomitant	 cardiovascular	
diseases.		
Table	16:	MS	patients’	and	healthy	control	participants’	cohort	characteristics.		
	 RRMS	(n=31)	 HC	(n=31)	 P*	
Age,	years	 38	(34-48)	 40	(30-49)	 0.43	
BMI,	kg/m2	 23.3	(21.3-25.6)	 23.7	(22.4-25.8)	 0.45	
Blood	pressure	systolic,	mmHg	 120	(112-131)	 123	(106-126)	 0.25	
Blood	pressure	diastolic,	mmHg	 78	(67-87)	 78	(69-86)	 0.91	
CRP,	mg/L	 0.55	(0.4-1.6)	 0.9	(0.4-1.5)	 0.45	
%	Females	(n)	 77.4	(24)	 77.4	(24)	 0.99	
%	Current	non-smokers	(n)	 96.8	(30)	 96.8	(30)	 0.99	
Duration	of	disease,	years		 6.15	(2.7-10.9)	 n/a	 n/a	
EDSS	 2	(0.5-2.5)	 n/a	 n/a	
SDMT	 0.5	(0-1)	 0	(-0.5-0.5)	 0.13	
MADRS	 2	(1-3)	 1	(0-2)	 0.12	
BDI-II	 4	(1-7)	 0	(0-2)	 0.01	
BAI	 3	(1-9)	 2	(0-5)	 0.02	











As	 described	 in	 2.1,	 all	 MS	 patients	 recruited	 for	 the	 study	 were	 in	 remission	 and	 on	
stable	immunomodulatory	therapy	(all	inclusion	criteria	listed	in	Table	4).	The	aim	was	to	
omit	any	effects	related	to	non-stable	and	non-immunomodulatory	medication	as	well	as	














Five	 patients	 on	 additional	 medications	 were	 included	 due	 to	 the	 year-long	 stable	
medication.	 Amongst	 them,	 four	 patients	 taking	 L-Tyroxin	 or	 Thyronajod	 (thyroiditis	
medication)	for	more	than	three	years	and	one	patient	taking	Simvastatin	(blood	pressure	
medication)	for	ten	years.	
Patients	 and	HC	 participants	were	 asked	 during	 the	 clinical	 assessment	whether	 family	
members	 are	 diagnosed	 with	 MS.	 Three	 female	 MS	 patients	 reported:	 two	 cousins	
(maternal	and	paternal	sides),	great-grandmother	paternal	side	and	twin	sister.	One	male	















Figure	 16:	Within	 group	 comparisons	 of	 differential	 blood	 parameters	 in	MS	 patients	











in	 MS	 patients	 and	 HC	 participants.	 Whole	 blood	 was	 analyzed	 in	 a	 certified	 routine	
laboratory:	Labor	Berlin,	Berlin,	Germany.	Blood	was	drawn	after	a	12	hour	fasting	period	
and	 analyzed	 on	 the	 same	 day.	 HDL:	 n=31	 pairs.	 LDL:	 n=31	 pairs.	 CRP:	 n=30	 pairs.	
Wilcoxon	 signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	 HDL:	 high	






































































To	 analyze	 and	 compare	 immunometabolic	 profiles	 in	 specific	 PBMC	 subpopulations,	





To	 ensure	 metabolic	 assay	 validity	 and	 test	 data	 compared	 to	 available	 literature	 on	
human	 immune	 cell	 energy	 metabolism,	 within	 group	 comparisons	 of	 the	 real-time	
energy	states	of	immune	cells	from	the	healthy	participant	cohort	were	performed.		
Figure	18	shows	the	kinetic	profile	of	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells	





significantly	 lower	 basal	 OCR	 values	 compared	 to	 non-CD4+/CD8+	 T	 cells	 (n=24	 pairs,	









Figure	18:	Within	group	 comparisons	 in	 the	HC	participant	 cohort	 showed	adapted	metabolic	
profiles	 in	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells.	The	data	was	generated	in	real-
time	 with	 unstimulated	 cells	 under	 basal	 conditions,	 in	 response	 to	 oligomycin,	 FCCP	 and	
Rotenone	and	Antimycin	A	using	a	Seahorse	XFe	96	Analyzer	(Agilent).	(A)	kinetic	profile	of	OCR	
values	of	CD4+	T	cells,	CD8+	T	cells	and	non-CD4+/CD8+	T	cells.	BR	and	MR	are	exemplarily	colored	
for	 non-CD4+/CD8+	 T	 cells.	 BR	 measured	 at	 third	 time	 point	 before	 oligomycin	 injection,	 MR	
measured	 after	 FCCP	 injection.	 (B)	BR:	 CD4+	 T	 cells:CD8+	 T	 cells	 (n=24	 pairs),	 CD4+	 T	 cells:non-
CD4+/CD8+	T	 cells	 (n=23	pairs),	CD8+	T	 cells:non-CD4+/CD8+	T	 cells	 (n=23	pairs).	 (C)	MR:	CD4+	T	
cells:CD8+	T	cells	 (n=24	pairs),	CD4+	T	cells:non-CD4+/CD8+	T	cells	 (n=24	pairs),	CD8+	T	cells:non-
CD4+/CD8+	T	cells	(n=23	pairs).	(A)	Mean	and	SEM	calculated	per	condition	for	each	time	point.	(B,	
C)	Wilcoxon	 signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed	 for	 BR	 and	MR.	
OCR:	 oxygen	 consumption	 rate,	 BR:	 basal	 respiration,	MR:	maximal	 respiration,	 FCCP:	 Carbonyl	
cyanide-4-(trifluoromethoxy)phenylhydrazone,	HC:	healthy	control,	MS:	multiple	sclerosis.				
	
In	 summary,	 using	 the	 Seahorse	 XFe	 96	 Analyzer,	 current	 literature	 data	 could	 be	
confirmed	 and	 provided	 valid	 results	 for	 measuring	 immunometabolic	 states	 of	





CD4+	 T	 cells	 have	 been	 shown	 to	 play	 a	major	 role	 in	MS	 pathogenesis	 and	 area	main	
target	 in	current	treatment.	Therefore,	 it	was	of	great	 interest	to	analyze	mitochondrial	
respiration	 in	 this	cell	population	and	generate	an	 immunometabolic	profile	 in	order	 to	
further	investigate	the	role	in	MS	disease.	
Following	 MACS	 purification,	 CD4+	 T	 cells	 from	MS	 patients	 and	 HC	 participants	 were	
analyzed	 in	 the	 Seahorse	 XFe	 96	 Analyzer.	 CD4+	 T	 cells	 from	 MS	 patients	 showed	
significantly	 lower	BR	 (p≤0.001),	MR	 (p≤0.01),	 spare	 respiratory	 capacity	 (SRC)	 (p≤0.01)	







Figure	 19:	 Impaired	metabolic	 profile	 of	 CD4+	 T	 cells	 in	MS	 patients	 compared	 to	HC	
participants.	The	data	was	generated	in	real-time	under	basal	conditions,	in	response	to	
oligomycin,	 FCCP	 and	 Rotenone	 and	 Antimycin	 A	 using	 a	 Seahorse	 XFe	 96	 Analyzer	
(Agilent).	(A)	Kinetic	profile	of	OCR	values	of	CD4+	T	cells.	Colored	displays	are	exemplarily	
shown	 for	HC.	 (B)	BR	n=23	pairs.	 (C)	MR	n=22	pairs.	 (D)	 SRC	n=23	pairs.	 (E)	NMR	n=20	
pairs.	 (F)	 ATP	 production	 n=23	 pairs.	 (G)	 PL	 n=23	 pairs,	 p=0.13.	 (A)	 Mean	 and	 SEM	
calculated	per	group	for	each	time	point.	(B-G)	Wilcoxon	signed-rank	test,	medians	with	
interquartile	ranges	are	displayed.	OCR:	oxygen	consumption	rate,	BR:	basal	respiration,	





Complementary	 to	 CD4+	 T	 cells,	 CD8+	 T	 cells	 have	 been	 found	 to	 be	modulated	 in	MS	
pathology	 and	 are	 targeted	 in	 current	 MS	 medication.	 The	 aim	 was	 to	 generate	 a	
mitochondrial	 respiration	 profile	 of	 CD8+	 T	 cells	 from	 MS	 patients	 providing	 greater	
insights	 into	 autoimmune	 mechanisms	 in	 MS	 disease	 and	 the	 contributions	 of	 energy	
metabolism	of	both	T	cell	subpopulations.			
CD8+	 T	 cells	 were	 purified	 and	 prepared	 for	 Seahorse	 XFe	 96	 Analyzer	 measurements.	














signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	 OCR:	 oxygen	
consumption	rate,	BR:	basal	respiration,	MR:	maximal	respiration,	SRC:	spare	respiratory	
capacity,	NMR:	non-mitochondrial	 respiration,	ATP:	Adenosine	 triphosphate,	PL:	proton	
leakage,	 FCCP:	 Carbonyl	 cyanide-4-(trifluoromethoxy)phenylhydrazone,	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
3.2.4 Mitochondrial	Energy	Metabolism	Profile	of	non-CD4+/CD8+	T	cells		
















Figure	 21:	 Metabolic	 profile	 of	 mitochondrial	 respiratory	 capacity	 does	 not	 differ	 in	 non-
CD4+/CD8+	 T	 cells	 from	MS	 patients	 compared	 to	 HC	 participants.	 The	 data	was	 generated	 in	
real-time	under	basal	conditions,	in	response	to	oligomycin,	FCCP	and	Rotenone	and	Antimycin	A	
using	a	Seahorse	XFe	96	Analyzer	 (Agilent).	(A)	Kinetic	profile	of	OCR	values	of	non-CD4+/CD8+	T	
cells.	Colored	displays	are	exemplarily	 shown	 for	HC.	 	 (B)	BR	n=24	pairs.	 (C)	MR	n=24	pairs.	 (D)	
SRC	n=24	pairs.	(E)	NMR	n=23	pairs.	(F)	ATP	production	n=24	pairs.	(G)	PL	n=24	pairs.	 (A)	Mean	
and	SEM	calculated	per	group	for	each	time	point.	(B-G)	Wilcoxon	signed-rank	test,	medians	with	
interquartile	 ranges	 are	 displayed.	 OCR:	 oxygen	 consumption	 rate,	 BR:	 basal	 respiration,	 MR:	
maximal	 respiration,	 SRC:	 spare	 respiratory	 capacity,	 NMR:	 non-mitochondrial	 respiration,	 ATP:	
Adenosine	 triphosphate,	 PL:	 proton	 leakage,	 FCCP:	 Carbonyl	 cyanide-4-
(trifluoromethoxy)phenylhydrazone,	HC:	healthy	control,	MS:	multiple	sclerosis.															
	










cell	 fractions	 was	 complemented	 with	 data	 on	 glycolytic	 immunometabolism,	 thereby	
testing	for	compensatory	energy	pathways	and	cellular	activation	status.		
Figure	22	 summarizes	 the	kinetic	profiles	as	well	 as	basal	 (measurement	 three	on	 time	
axis)	and	maximal	Extracellular	Acidification	Rate	 (ECAR)	 (highest	value	after	oligomycin	
injection	 on	 time	 axis)	 for	 all	 three	 cell	 populations.	 For	 comparability	 purposes	 with	
previously	 shown	 OCR	 graphs,	 all	 time	 points	 are	 displayed	 in	 the	 kinetic	 profile.	
However,	 time	 points	 following	 FCCP	 injection	 were	 excluded	 from	 the	 analysis	 of	
glycolytic	activity,	because	the	data	compromise	additional	metabolic	pathway	activities	



























The	 previous	 figures	 showed	mitochondrial	 and	 glycolytic	 activity	 of	 purified	 CD4+	 and	
CD8+	T	cells	as	well	as	non-CD4+/CD8+	T	cells.	To	summarize	and	illustrate	the	changes	in	
OCR	and	ECAR	 from	basal	 levels	 (third	value	on	 time	axis	 in	previous	kinetic	graphs)	 to	













the	MS	 patient	 cohort,	 non-CD4+/CD8+	 T	 cells	 showed	 a	 trend	 toward	 increased	 basal	










cells	MS	 (n=23):	 basal	 OCR:	 16.8	 (2.5),	 basal	 ECAR:	 11.3	 (1.5),	max.	 OCR:	 101.2	 (24.7),	
max.	ECAR:	19.6	(2.8).	CD8+	T	cells	HC:	basal	OCR:	17.5	(2.9),	basal	ECAR:	12.6	(1.8),	max.	
OCR:	87.2	(18.1),	max.	ECAR:	22.9	(3.2).	(C)	non-CD4+/CD8+	T	cells	MS	(n=24):	basal	OCR:	
24.3	 (2.9),	 basal	 ECAR:	 54.0	 (5.1),	max.	 OCR:	 139.1	 (24.2),	max.	 ECAR:	 61.3	 (7.4).	 non-
CD4+/CD8+	 T	 cells	 HC:	 basal	 OCR:	 20.9	 (2.0),	 basal	 ECAR:	 44.6	 (3.6),	 max.	 OCR:	 117.0	
(17.0),	max.	ECAR:	54.7	(4.3).	Means	with	SEM	(in	brackets)	calculated.	For	some	points,	
the	error	bars	would	be	shorter	than	the	height	of	the	symbol,	therefore,	in	these	cases	









well	 as	 glycolytic	 respiration,	 providing	 central	 insights	 into	 immunometabolism	 in	MS	
disease.	
To	further	investigate	the	complexity	of	immune	cell	subpopulations	and	gain	insight	into	
specific	 cell	 signaling,	 flow	 cytometry	 analyses	 of	 MS	 patient’s	 and	 HC	 participant’s	
PBMCs	were	performed.		
3.3 	Flow	Cytometry	Analyses		
Metabolic	analyses	showed	 impaired	energy	profiles	 in	 immune	cells	 from	MS	patients.	
Predominantly,	enriched	CD4+	T	cells	 from	MS	patients	displayed	an	overall	decrease	 in	
mitochondrial	 and	 glycolytic	 activity.	 To	 investigate	 the	 phenotype	 of	 specific	 cell	
subpopulations,	 PBMCs	 were	 analyzed	 by	 flow	 cytometry.	 Complementing	 the	
phenotypic	 characterization	 of	 the	 PBMCs,	 the	 analysis	 of	 a	 potential	 impairment	 in	
mitochondrial	respiration	as	well	as	T	cell	exhaustion	was	of	great	interest.	Therefore,	the	
mitochondrial	 membrane	 protein	 CPT1a,	 essential	 in	 fatty	 acid	 transfer	 into	
mitochondria,	and	the	cellular	exhaustion	marker	PD-1,	upregulated	in	ongoing	immune	




The	 phenotype	 of	 PBMCs	 from	 MS	 patients	 and	 their	 correspondingly	 matched	 HC	
participants	was	analyzed	pairwise	in	flow	cytometry.	Antibody	staining	panels	are	listed	
in	Table	12.	There	were	no	significant	differences	 in	the	relative	number	of	CD4+	T	cells	
(p=0.59),	 CD8+	 T	 cells	 (p=0.24),	 regulatory	 T	 cells	 (T	 regs)	 (p=0.86)	 as	 well	 as	 classical	











CD14+	 CD16+	 intermediate	 monocytes	 and	 CD14+	 CD16+high	 non-classical	 monocytes.	 Wilcoxon	
signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	 ,	 HC:	 healthy	 control,	 MS:	
multiple	sclerosis.	
	







Comparing	 and	 analyzing	 frequencies	 of	 T	 cell	 subtypes	 based	 on	 the	 expression	 of	
chemokine	 receptors,	 MS	 patients	 show	 a	 decreased	 frequency	 of	 CD8+	 CCR6+	 T	 cells	





not	 show	 statistically	 significant	 differences	 in	 frequencies	 between	 both	 cohorts	 (all	
p≥0.31,	appendix	Figure	37).	
Analyzing	 non	 T	 cell	 populations,	 an	 increased	 amount	 of	 B	 cells	 was	 detected	 in	 MS	
patients’	PBMCs	(n=29	pairs,	p≤0.01,	appendix	Figure	38).		Furthermore,	the	frequency	of	
cytotoxic	 NK	 cells	 was	 significantly	 decreased	 (p≤0.001)	 and	 regulatory	 NK	 cells	 were	
significantly	increased	in	MS	patients	(p≤0.001,	appendix	Figure	39).		
In	conclusion,	no	major	differences	in	frequencies	of	CD4+	and	CD8+	T	cell	subpopulations	





To	 confirm	 the	 specificity	 of	 the	 CPT1a	 antibody,	 its	 isotype	 control	 was	 used	 to	 stain	
PBMCs	from	an	MS	patient-HC	participant	pair.	Figure	25	displays	exemplary	histograms	
in	 major	 T	 cell	 subpopulations	 comparing	 the	 CPT1a	 antibody	 and	 isotype	 control	
staining.	The	isotype	control	stainings	did	not	show	detectable	background	fluorescence,	





HC	 participant	 pair	 using	 the	 CPT1a	 antibody	 (AlexaFluor®488,	 clone	 8F6AE9,	 Abcam)	 and	 its	





Total	 CD4+	 T	 cells	 and	 CD4+	 helper	 T	 cell	 populations,	 Th0,	 Th1,	 Th2,	 Th17	 and	 Th1/17	





Figure	 26:	 CD4+	 T	 cells	 and	 CD4+	 helper	 T	 cell	 subpopulations	 show	 increased	 MFI	 of	 CPT1a	
analyzed	by	flow	cytometry.	 (A,C)	Between	group	analyses	for	MS	patients	and	HC	participants	
are	shown,	n=29	pairs.	(B,	D)	Histograms	show	CPT1a	expression	in	a	representative	MS	patient-
HC	 participant	 pair	 in	 the	 corresponding	 cell	 subsets.	Wilcoxon	 signed-rank	 test,	medians	with	














cytometry.	 (A)	 Between	 group	 analyses	 for	 MS	 patients	 and	 HC	 participants	 are	 shown.	 n=29	
pairs.	(B)	Histograms	show	CPT1a	expression	in	the	corresponding	cell	subsets	of	a	representative	
MS	patient-HC	participant	pair.	Wilcoxon	signed-rank	test,	medians	with	interquartile	ranges	are	







groups.	 It	 may	 most	 likely	 be	 that	 these	 cells	 are	 non-chemokine	 receptor	 expressing	










Wilcoxon	signed-rank	 test,	medians	with	 interquartile	 ranges	are	displayed.	CCR:	CC	chemokine	
receptor,	 CXCR3:	 CXC	 chemokine	 receptor	 3,	 MFI:	 Median	 Fluorescent	 Intensity,	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
Furthermore,	CPT1a	MFI	was	analyzed	 in	B	 cells,	NK	 cell	 subpopulations	and	monocyte	




In	 conclusion,	 CD4+	 helper	 T	 cells,	 T	 regs,	 naïve	 T	 regs	 as	 well	 as	 CD8+	 T	 cell	
subpopulations	and	cytotoxic	NK	cells	showed	increased	levels	of	CPT1a	in	the	MS	patient	
cohort	compared	to	the	HC	participant	cohort.		
These	 results	 suggest	 a	 dysfunction	 in	mitochondrial	 energy	 regulation	 in	MS	 patient’s	
immune	cell	subtypes,	predominantly	in	CD4+	T	cell	subpopulations	and	therefore	add	to	













cells.	 Wilcoxon	 signed-rank	 test,	 medians	 with	 interquartile	 ranges	 are	 displayed.	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
PD-1	expression	analyses	in	CD4+	and	CD8+	T	cell	subpopulations	(naïve,	memory,	effector	
and	helper	 T	 cells	 as	well	 as	 T	 regs)	did	not	 show	changed	patterns	 comparing	 the	MS	
patient	and	HC	participant	cohorts.		
Taken	together,	the	results	indicate	that	PD-1	expression	patterns	are	not	altered	in	T	cell	
subpopulations	 from	 MS	 patients	 compared	 to	 HC	 participants	 and	 therefore	 do	 not	
indicate	a	PD-1-mediated	cellular	exhaustion	phenotype.		
3.3.4 IL7-Rα 	and	IL2-Rα 	expression	in	conventional	T	cells		
IL7-Rα	 (CD127)	 and	 IL2-Rα	 (CD25)	 play	 essential	 roles	 in	 CD4+	 T	 cell	 development	 and	
homeostasis.	 In	this	study,	the	markers	were	primarily	used	to	discriminate	T	regs	from	
CD4+	 CD25-	 CD127+	 conventional	 T	 cells.	 In	 addition	 to	 using	 IL7-Rα	 and	 IL2-Rα	 for	
phenotyping,	 the	 MFI	 was	 analyzed	 in	 CD4+	 CD25-	 CD127+	 conventional	 T	 cells,	 which	














n=29	pairs,	p=0.066	 (B)	and	 IL2-Rα	n=28	pairs,	p=0.844	 (C).	Wilcoxon	signed-rank	 test,	medians	








(defined	 as	 all	 PBMCs	 except	 for	 CD4+	 and	 CD8+	 T	 cells).	 In	 mRNA	 gene	 expression	
analyses,	mechanisms	 like	 post-translational	 protein	modifications	 can	 be	 omitted	 and	
direct	gene	transcription	measured.			
Linking	 pro-inflammatory	 signaling	 pathways	 along	 with	 energy	 metabolism	 activation	
pathways	 were	 the	 main	 interest.	 Therefore,	 genes	 encoding	 key	 cellular	 signaling	
proteins	that	integrate	metabolism	and	inflammation	were	chosen	for	analysis	and	mRNA	






Additionally,	 to	further	 investigate	the	 impact	and	relevance	of	stress	response	systems	
on	 immune	 cells	 in	 MS	 disease	 and	 to	 accompany	 data	 from	 circadian	 hypothalamic-
pituitary-adrenal	(HPA)	axis	activity	measured	by	salivary	cortisol,	mRNA	expression	levels	





expression	 levels	 between	 the	 MS	 patient	 cohort	 and	 HC	 participant	 cohort	 were	
performed.	 There	 were	 no	 significant	 differences	 in	 mRNA	 expression	 levels	 of	 the	
analyzed	genes	in	CD4+	T	cells	(n=26	pairs,	p>0.1)	and	CD8+	T	cells	(n=26	pairs,	p>0.1).	In	
non-CD4+/CD8+	T	 cells,	TNF-α	 levels	were	elevated	 in	MS	patients	 (n=25	pairs,	 p≤0.05)	
and	 there	was	 a	 trend	 toward	 increased	 CPT1a	 expression	 levels	 in	MS	 patients	 (n=25	






Figure	 31:	 Analysis	 mRNA	 gene	 expression	 in	 CD4+	 T	 cells,	 CD8+	 T	 cells	 and	 non-
CD4+/CD8+	T	cells	from	MS	patients	and	HC	participants.	Expression	analyses	for	GLUT1,	
NFκB1,	NFκB3,	 TNFα	and	 CPT1a	 are	 shown.	 	The	 ratio	 between	 NFκB1	and	 NFκB3	was	
determined	 for	NFκB	expression.	 CD4+	 T	 cells:	 n=26	pairs,	 p>0.1	 for	 all	 genes	 analyzed.	
CD8+	T	cells:	n=26	pairs,	p>0.1	for	all	genes	analyzed.	non-CD4+/CD8+	T	cells:	n=25	pairs,	
p>0.1	 if	 not	 depicted.	 Gene	 transcript	 levels	 were	 assessed	 relative	 to	 housekeeping	
genes	 IPO8	 and	 TBP	 following	 ΔΔCT.	 Wilcoxon	 signed-rank	 test	 with	 medians	 with	
interquartile	ranges	are	displayed.	CPT1a:	Carnitine	palmitoyltransferase	I	isoform	a,	TNF-





GR	 and	 GILZ	 gene	 expression	 were	 analyzed	 in	 CD4+	 T	 cells,	 CD8+	 T	 cells	 and	 non-
CD4+/CD8+	 T	 cells	 from	 MS	 patients	 and	 HC	 participants.	 Significant	 differences	 were	




MS	patients	(n=27	pairs,	p≤0.05)	and	 in	GR	mRNA	expression	 levels	 in	CD8+	T	cells	with	




non-CD4+/CD8+	 T	 cells	 from	MS	 patients	 and	 HC	 participants.	 CD4+	 T	 cells:	GR	 n=26	
pairs,	GILZ	n=27	pairs.	CD8+	T	cells:	GR	and	GILZ	n=26	pairs.	non-CD4+/CD8+	T	cells:	GR	and	
GILZ	 n=24	 pairs.	 Gene	 transcript	 levels	 were	 assessed	 relative	 to	 housekeeping	 genes	
IPO8	and	TBP	following	ΔΔCT.	Wilcoxon	signed-rank	test	with	medians	with	interquartile	


























































































Figure	 33:	No	difference	 in	morning	and	 evening	 salivary	 cortisol	 levels	 between	MS	patients	
and	HC	participants.	On	two	consecutive	days,	two	morning	(after	awakening,	time	point	1	and	3)	
and	two	evening	(at	9pm,	time	point	2	and	4)	saliva	samples	were	analyzed.	n=25	pairs.	Day	one,	





Correlation	 analyses	 were	 performed	 in	 order	 to	 observe	 associations	 between	 case	
report	form	(CRF)	data	and	metabolic	and	flow	cytometry	results.	From	CRF	data,	the	MS	
progression	 index	was	 chosen	 for	 correlation	 analyses.	 	 It	 is	 calculated	 by	 dividing	 the	
Expanded	Disease	Status	Scale	(EDSS)	score	by	disease	duration	 	 (the	time	between	the	
clinical	 MS	 diagnosis	 and	 date	 of	 the	 study	 visit)	 [136].	 The	 EDSS	 allows	 the	 rating	 of	
disease	progression	on	a	scale	 from	0	 to	10	and	 thereby	defines	 the	patient’s	disability	
status	 based	 on	 the	 physical	 functional	 assessment.	 The	 disease	 duration	 takes	 into	
account	 for	 how	 long	 the	 patients	 have	 been	 diagnosed	 with	MS.	 	 Therefore,	 the	MS	
progression	 index	not	only	provides	 information	about	MS	duration,	but	also	takes	 into	
account	the	patient’s	disability	status.		
To	 recollect	 briefly,	 in	 this	 study,	 the	median	 EDSS	 score	was	 2	 (with	 the	 interquartile	








Correlation	 analyses	 of	 CPT1a	 in	 CD8+	 T	 cells	 and	 MS	 progression	 index	 revealed	 a	
negative	correlation	(rS=-0.52,	p=0.01)	(Figure	34	B).	Similar	to	CD4+	T	cells,	in	CD8+	T	cells,	
CPT1a	decreases	with	increasing	progression	index.		
Correlation	 analyses	 between	 MS	 progression	 index	 and	 Seahorse	 XFe	 96	 metabolic	
analyzer	 basal	 respiration	 data	 were	 performed	 for	 CD4+	 and	 CD8+	 T	 cell	 subtypes	







(A)	 CD4+	 and	 (B)	 CD8+	 T	 cells.	 n=23.	 Basal	 respiration	 data	 from	 Seahorse	 XFe	 96	 analyzer	
metabolic	assay	analyses	were	correlated	with	the	MS	disease	progression	index	in	(C)	CD4+	and	
(D)	 CD8+	 T	 cells.	 n=18.	 rS=	 Spearman	 correlation	 coefficient.	 EDSS:	 Expanded	 Disability	 Status	
Scale,	 CPT1a:	 Carnitine	 palmitoyltransferase	 I	 isoform	 a,	 HC:	 healthy	 control,	 MS:	 multiple	
sclerosis.	
Taken	 together,	 the	data	 shows	a	negative	 correlation	between	CPT1a	and	 the	disease	









Providing	 a	 solid	MS	 patient	 and	 HC	 participant	 background	with	 respect	 to	 biological	
samples	 (PBMCs	and	saliva)	as	well	as	case	report	 form	data	 is	 the	basis	 for	pre-clinical	







analyzed	 providing	 a	 relatively	 large	 cohort	 of	 human	 clinical	 and	 corresponding	 pre-
clinical	 data.	 Patients	 and	 participants	 had	 no	 significant	 physical	 or	 psychological	
comorbidities	 and	 medications	 other	 than	 immunomodulatory	 therapy.	 Furthermore,	
also	 critical	 for	 the	 extensive	metabolic	 analyses,	 all	 patients	 and	 participants	 had	 not	
eaten	 for	 12	 hours	 prior	 to	 the	 blood	 draw	 and	 PBMCs	 were	 processed	 within	 thirty	





without	 treatment,	with	 INF-β1a	treatment	and	healthy	controls	 [120].	While	 the	study	
provided	critical	metabolic	data,	the	patients	and	control	participants	were	not	matched	
and	not	fasting	for	a	time	period	prior	to	the	study	visit	whole	blood	draw.	De	Riccardis	
and	 colleagues	provided	data	on	 immunometabolism	 in	 a	 cohort	 of	 treatment-free	MS	
patients	in	2015	[121].	RRMS	patients	and	HC	participants	were	matched	for	age,	but	not	




results	 of	 these	 studies	with	 respect	 to	 the	data	provided	 in	 the	DENIM	 study	 in	more	
detail.	






The	 DENIM	 study	 considers	 key	 systemic	 modulators	 of	 inflammation	 and	 examines	
patients	 and	 HC	 participants	 in	within	 group	 pairwise	 analyses.	 It	 is	 important	 to	 note	
again	 that	 the	 aim	 of	 the	 study	 was	 to	 examine	 patients	 in	 remission	 and	 the	 results	





It	 is	 known	 that	 inflammation	 in	 disease	 states	 leads	 to	 a	 shift	 in	 the	 immune	 cell	
repertoire	 in	 human.	 Depending	 on	 the	 intruding	 pathogen,	 e.g.	 extra-	 or	 intracellular	
bacteria,	viruses	or	worms,	specific	immune	cell	subtypes	are	activated	and	proliferation	
processes	 induced	to	 fight	the	 infection.	 In	autoimmune	diseases	 like	MS,	analyzing	the	
specific	immune	cell	phenotype	plays	a	central	role	to	better	understand	the	disease	and	
the	 cellular	 and	 humoral	 factors	 contributing	 to	 the	 activation	 of	 the	 immune	 system	
against	 self-structures.	 These	 analyses	 can	 help	 to	 allude	 to	 disease	 causing	 factors,	
development	and	progression	as	well	as	potentially	hint	to	new	therapeutic	targets.	
In	 the	 current	 study,	 a	 comprehensive	 PBMC	 immune	 cell	 phenotyping	was	 performed	
with	 both	 cohorts	 to	 compare	 phenotype	 alterations	 in	 MS	 disease	 versus	 healthy	
individuals.	Additionally,	intracellular	and	cell	surface	molecules	were	analyzed	to	include	
metabolic	 and	 T	 cell	 exhaustion	 markers.	 Routine	 whole	 blood	 analyses	 showed	




lymphocytes	 measured	 by	 flow	 cytometry	 did	 not	 show	 differences	 between	 both	
cohorts.	Hence,	although	MS	patients	show	decreased	absolute	numbers	of	lymphocytes,	
the	 distribution	 of	 T	 cell	 subpopulations	 is	 not	 altered	 in	 the	 MS	 patient	 cohort.	
Comparable	levels	of	major	CD4+	T	cell	subpopulations	including	Tregs	were	detected	in	
MS	patients	and	HC	participants.	Solely	CD8+	CCR6+	effector	T	cells	showed	alterations	of	
the	phenotypic	make	up	with	a	decreased	 frequency	 in	MS	patients.	 Finally,	memory	T	
cell	subpopulations	did	not	show	alterations	between	MS	patients	and	HC	participants.	




they	 migrate	 to	 inflammatory	 sites,	 induce	 the	 formation	 of	 lesions	 and	 with	 that	
neuronal	 demyelination.	 Therefore,	 immunomodulatory	 drugs	 approved	 for	 RRMS	
treatment	 are	 effective	 in	 preventing	 disease	 progression	 by	 targeting	 different	
mechanisms	 of	 actions	 of	 T	 cells	 and	 other	 immune	 cells.	 Briefly,	 the	 mechanisms	 of	
action	 include:	 the	 prevention	 of	 T	 cell	 activation	 and	 division,	 the	 inhibition	 of	 pro-
inflammatory	 cytokine	 secretion,	 the	 trapping	 of	 T	 cells	 in	 lymph	 nodes	 and	with	 that	
prevention	of	their	migration	into	the	CNS,	inhibition	of	B	cell	function	and	the	induction	
of	Tregs	[2],[140]–[142].		
To	 date,	 it	 could	 be	 shown	 that	 the	 frequency	 of	 Tregs	 in	 PBMCs	 from	RRMS	 patients	
does	 not	 seem	 to	 be	 altered,	 but	 may	 be	 accompanied	 by	 a	 decreased	 suppressive	
capacity	 [143],[144].	 A	 study	 by	 Feger	 et	 al.	 revealed	 increased	 CD4+	 CD25+	 Treg	
frequencies	in	the	CSF	of	MS	patients	with	neuroinflammation	and	no	differences	of	Treg	
frequency	in	MS	patient’s	PBMCs	[143].	These	findings	were	accompanied	by	a	reduced	
immunosuppressive	 capacity	 of	 Tregs.	 The	 authors	 suggest	 that	 peripheral	 Tregs	 are	
recruited	 from	 the	 blood	 to	 the	 CNS	 of	MS	 patients	 with	 ongoing	 neuroinflammation.	
They	further	discuss	their	findings	by	stating	that	Tregs	enrichment	in	the	cerebral	spinal	
fluid	(CSF)	of	the	CNS	may	not	be	sufficient	to	fight	neuroinflammation.	These	results	are	








CSF	 analyses.	 Furthermore,	 the	 interaction	 with	 other	 immune	 cell	 populations	 with	
regard	to	cell	activation	and	cytokine	secretion	should	be	considered.		
Data	 on	 phenotypic	 alterations	 in	 CD4+	 T	 cell	 subpopulations	 indicate	 that	 it	 may	 not	
merely	 be	 the	 quantity	 of	 cells	 or	 the	 phenotypic	 make	 up	 leading	 to	 MS	 disease	
development	 and	 progression,	 but	 cell	 specific	 dysfunctions	 including	 potential	
alterations	 in	 immunometabolic	 signaling,	 which	 may	 contribute	 to	 auto-reactive	
processes	observed	in	MS	disease.	
While	the	precise	functions	of	CD8+	effector	T	cell	subpopulations	are	still	 the	center	of	
research,	 CD8+	 CCR6+	 T	 cells	 have	 been	 shown	 to	 be	 essential	 in	 Th17-mediated	 pro-
inflammatory	 immune	 responses	 [50].	 A	 decreased	population	of	 CD8+	 CCR6+	 T	 cells	 in	
PBMCs	of	MS	patients	may	indicate	the	transmigration	of	these	cells	from	the	peripheral	
blood	 to	 potential	 inflammatory	 sites.	 However,	 the	 observed	 decrease	 of	 this	 cell	
population	 in	the	current	study	requires	future	detailed	analyses	 in	order	to	conclude	a	
potential	 link	 to	 MS	 disease	 progression.	 Studies	 by	 other	 research	 groups	 have	 not	
described	this	effect	in	MS	disease	to	date.	




CD4+	 memory	 T	 cell	 phenotypes	 in	 MS	 patients	 and	 the	 effect	 of	 different	
immunomodulatory	medications:	decreases	in	TCM	cells	in	patients	treated	with	INF-β	or	
glatiramer	acetate	[147],	increases	in	TCM	cells	in	patients	treated	with	fingolimod	[148],	




patient	 cohort.	 A	 study	 by	 Haegele	 et	 al.	 analyzed	 16	 RRMS	 patients	 and	 compared	
peripheral	blood-derived	and	CSF-derived	memory	CD4+	and	CD8+	T	 cell	 subsets	 to	age	
and	 sex-matched	healthy	 controls	 [151].	 Patients	were	 in	 active	 disease	 states	 or	 after	
relapse	and	free	of	immunomodulatory	therapy.	The	authors	detected	increased	CD8+	TEM	




discuss	 their	 finding	by	potential	 systemic	 immune	activation	and	 increased	MS	disease	
activity.	Furthermore,	Haegele	and	colleagues	observed	a	reduction	in	CD8+	TEM	T	cells	in	
the	 CSF	 of	 MS	 patients	 compared	 to	 the	 patient’s	 corresponding	 peripheral	 blood	
samples.	The	authors	state	that	this	may	be	due	to	CD8+	TEM	T	cells	infiltrating	brain	tissue	
and	 inducing	 inflammatory	 responses	 [151].	 Alterations	 in	 CD4+	memory	 T	 cell	 subsets	




memory	 T	 cell	 subsets	 in	 MS	 remission	 phase	 and	 their	 impact	 on	 CNS	 infiltration.	
However,	 considering	 the	 importance	 of	 immunometabolism,	 patient	 and	 control	
matching	should	be	considered.	
Taken	 together,	 the	 phenotypic	 analyses	 of	 the	 CD4+	 and	 CD8+	 T	 cell	 subpopulations	
showed	 little	 or	 no	 changes	 in	 the	MS	 patient	 cohort	 compared	 to	 the	 HC	 participant	
cohort.	Therefore,	qualitative	analyses	may	hint	to	potential	dysfunctions	in	MS	patient’s	






their	 immediate	requirements,	however,	 little	 is	known	about	 immunometabolic	effects	









with	 the	 Seahorse	 XFe96	 analyzer	 and	 compared	 to	 a	 meticulously	 matched	 HC	
participant	cohort.		
It	 could	 be	 shown	 that	 CD4+	 T	 cells	 from	MS	 patients	 display	 a	 significantly	 decreased	
basal	mitochondrial	oxygen	consumption	rate.	Parameters	of	mitochondrial	function	like	
maximal	 respiration,	 cellular	 spare	 respiratory	 capacity	 as	 well	 as	 ATP	 production	 also	
showed	decreased	levels	in	the	MS	patient	cohort.	Only	measurements	of	mitochondrial	
proton	leakage	were	comparable	between	both	cohorts.	These	results	allude	to	reduced	
mitochondrial	 function	 in	 CD4+	 T	 cells	 from	MS	 patients.	 Furthermore,	 the	 analysis	 of	
glycolytic	activity	showed	decreased	levels	in	CD4+	T	cells	from	MS	patients-	hence,	these	
cells	 are	 not	 compensating	 decreased	 mitochondrial	 activity	 by	 increasing	 glycolysis.	
Contrary	 to	 the	observed	effects	 in	CD4+	T	cells,	CD8+	T	cells	 from	MS	patients	 showed	
metabolic	parameters	of	oxygen	consumption	as	well	as	glycolytic	activity	comparable	to	
those	 of	 the	 HC	 participant	 cohort.	 Interestingly,	 the	 observed	 effects	 in	 decreased	
immunometabolic	activity	are	CD4+	T	cell	specific	in	the	RRMS	patient	cohort.	
First	studies	on	immune	cell	metabolism	in	MS	patients	have	been	published	in	the	past	
three	 years.	 The	 study	 by	 La	 Rocca	 and	 colleagues	 detected	 decreased	 mitochondrial	
oxygen	 consumption	 rate	activity	 as	well	 as	 glycolytic	 activity	 in	 TCR-stimulated	PBMCs	
from	RRMS	patients	without	treatment	compared	to	HC	controls	[120].	No	difference	was	
found	 between	 HC	 and	 INF-β1a	 treated	 patients,	 however	 there	 were	 detectable	
differences	 in	mitochondrial	 respiration	between	 the	no-treatment	and	 INF-β1a	patient	
groups.	 Limitations	of	 the	 study	are	 that	mitochondrial	 respiration	of	 the	no-treatment	
cohort	 was	 analyzed	 in	 eleven	 patients	 only	 and	 compared	 to	 non-matched	 HC	
individuals.	 Whole	 PBMCs	 were	 analyzed	 and	 no	 distinction	 between	 different	 cell	
populations	 was	 made.	 Additionally,	 the	 authors	 did	 not	 consider	 sex	 effects,	 BMI,	
smoking	status	or	physical	or	psychological	 comorbidities.	No	 fasting	blood	draws	were	
analyzed.	Nevertheless,	 the	 study	provides	 first	 crucial	 data	on	emerging	differences	 in	
energy	metabolism	in	 immune	cells	 from	MS	patients	and	hints	to	 influences	of	current	
state	of	the	art	RRMS	medication	and	immunometabolic	function.		
The	current	study	sheds	 light	 into	the	mechanisms	of	 immunometabolic	dysfunctions	 in	






ETC	 in	 MS	 patients.	 In	 their	 2015	 study,	 De	 Riccardis	 and	 colleagues	 analyzed	 ETC	
complexes	 and	 cellular	 respiration	 in	 CD4+	 T	 cells	 from	 twelve	 unmedicated	 RRMS	
patients	 and	 compared	 the	 data	 to	 eight	 age-matched	 healthy	 individuals	 [121].	 The	
authors	detected	decreased	protein	 levels	of	ETC	complexes	 I	and	 IV	 in	RRMS	patients.	
These	 findings	 were	 associated	 with	 decreased	 oxygen	 consumption	 rates	 and	 ATP-
production	 levels	 in	 CD4+	 T	 cells	 from	 RRMS	 patients	 as	 well	 as	 increased	 levels	 of	
glycolysis	and	glycolysis-derived	ATP.	While	the	study	provides	a	relatively	low	number	of	
MS	patients	and	HC	participants,	 it	provides	crucial	data	on	ETC	impairments.	 Increased	
glycolytic	 activity	 was	 accompanied	 by	 increased	 GLUT1	 protein	 levels	 as	 well	 as	
increased	 lactate	 production,	 which	 the	 authors	 describe	 as	 a	 potential	 hint	 to	 an	
energetic	switch	from	OXPHOS	to	glycolysis	in	the	observed	cohort.		
To	the	best	of	knowledge,	detailed	mitochondrial	analyses	of	sorted	CD8+	T	cells	from	MS	
patients	 have	 not	 been	 published	 to	 date.	 Complementing	 the	 observed	 effects	 of	
impaired	mitochondrial	complex	function	in	CD4+	T	cells	by	De	Riccardis	and	colleagues,	it	




patients	 compared	 to	 healthy	 individuals.	 The	 impairment	 in	 complex	 I	 (NADH	
dehydrogenase)	 ETC	 activity	 observed	 by	 De	 Riccardis	 [152]	 alludes	 to	 potential	
connections	between	this	ETC	complex	impairment	and	increased	NADH	serum	levels	in	
patients.	 Taken	 together,	 these	 results	 strengthen	 the	 findings	 on	 immunometabolic	
dysfunctions	 in	 MS	 patients	 and	 should	 be	 taken	 into	 consideration	 when	 finding	
therapeutic	targets	in	future	investigations.		
Furthermore,	common	MS	symptoms	and	co-morbidities	including	fatigue	and	depression	
could	 be	 associated	 with	 impaired	 mitochondrial	 energy	 production,	 suggesting	 that	
dysregulated	 energy	 metabolism	 in	 immune	 cells	 may	 impact	 other	 organ	 systems,	






and	 the	 immune	 system	 is	 most	 noteworthy	 and	 has	 comprehensively	 been	 reviewed	
[153]–[155].	
The	significantly	decreased	 levels	of	ATP	production	 in	CD4+	T	cells	 in	 the	current	study	










contributing	 to	 citrate	 cycle	 energy	 production.	 Furthermore,	 maximal	 respiration	 and	
with	that	spare	respiratory	rates	did	not	reach	levels	detected	in	HC	participants,	which	
furthermore	 indicates	 decreased	 fitness	 levels	 of	 CD4+	 T	 cells	 from	 MS	 patients	 and	
comprehensive	impairments	in	cellular	energy	production.			
Adiele	et	al.	comprehensively	reviewed	the	 latest	 findings	on	 immunometabolic	defects	
related	to	MS	disease	in	their	2017	review	[156].	The	authors	systematically	discuss	key	
findings	including	the	contributing	factors	of	metal	metabolism	as	well	as	dysfunctions	in	
mitochondrial	 and	 oxygen	 metabolism	 on	 a	 cellular	 level	 in	 the	 blood	 and	 CNS.	 The	
research	articles	cited	provide	broad	evidence	that	metabolic	aspects	have	strong	effects	
on	 MS	 disease	 prevention,	 course	 and	 progression.	 The	 biochemical	 and	 molecular	











Comprehensive	 laboratory	 analyses	 of	 protein	 and	 gene	 expression	 as	 well	 as	 routine	
blood	testing	performed	with	the	MS	patient	and	HC	participant	samples	from	the	DENIM	





In	 this	 thesis,	 it	 could	 be	 shown	 that	 the	mitochondrial	membrane	 protein	 CPT1a	was	
significantly	 increased	 in	 all	 CD4+	 T	 cell	 subpopulations	 (Th1,	 Th2,	 Th17,	 Th1/17,	 Tregs)	
and	CD8+	effector	T	cell	subsets	in	the	MS	patient	cohort	compared	to	the	HC	participant	
cohort.	Memory	T	 cells	of	MS	patients	 showed	CPT1a	protein	 levels	 comparable	 to	 the	
ones	detected	in	the	HC	participant	cohort.	These	findings	are	observed	for	the	first	time	
in	 a	 human	MS	 study	 and	 hint	 to	 significant	 functional	 impairments	 in	 cellular	 energy	
metabolism	and	the	mitochondrial	membrane	protein.	Conventional	CD4+	T	cells	showed	
increased	 levels	 of	 CPT1a,	 a	 trend	 towards	decreased	 IL7-Rα	 and	no	 changes	 in	 IL2-Rα	
expression	in	MS	patients.	Furthermore,	cellular	PD-1	expression	analyses	did	not	reveal	
alterations	 in	 PD-1	 expression	 in	 T	 cell	 subpopulations	 in	 MS	 patients.	 Therefore,	 the	
observed	 findings	 in	metabolic	dysfunction	and	CPT1a	protein	expression	 in	CD4+	T	cell	
subsets	 were	 not	 accompanied	 by	 modified	 PD-1	 expression	 levels	 in	 MS	 patients.	
Routine	 blood	 analyses	 indicated	 a	 trend	 toward	 decreased	 serum	 HDL	 levels	 in	 MS	
patients	 adding	 to	 potential	 impairments	 in	 fatty	 acid	 utilization.	 Moreover,	 it	 was	










Various	 metabolic	 alterations	 may	 be	 causative	 of	 the	 observed	 increase	 in	 CPT1a	
expression	in	MS	patients’	T	cell	subpopulations	and	the	accompanied	overall	decrease	in	
mitochondrial	 respiration	 in	 CD4+	 T	 cells.	 T	 cell	 subpopulations	 may	 compensate	 the	
dysfunctional	protein	by	increasing	its	abundance	and	with	that	potentially	accumulate	a	
multitude	 of	 dysfunctional	 protein	 that	 is	 preventing	 regular	 mitochondrial	 respiration	
and,	overall,	hindering	cellular	signaling	 feedback	pathways	 involved	 in	CPT1a	signaling.		
In	 line	with	 the	described	 effects	 of	 energy	metabolism	on	 immune	 cells,	 the	 group	of	
Nieland	 showed	 that	 EAE	 symptoms	 can	 be	 alleviated	 completely	 by	 inhibiting	 CPT1a	
[157],[158].	 The	 group	 used	 etomoxir	 to	 inhibit	 CPT1a,	 thus	 decreasing	 mitochondrial	
fatty	acid	respiration	and	reversing	clinical	symptoms.	They	describe	their	findings	in	part	
by	 analyzing	 CPT1a	 mutations	 and	 show	 that	 MS	 patients	 frequently	 do	 not	 have	
mutations	 in	CPT1a,	while	healthy	 individuals	 frequently	show	CPT1a	mutations	 leading	
to	 reduced	or	overall	deleted	activity	of	 the	protein	 [158],[159].	The	group	 tested	mice	
and	rats	and	treated	them	with	either	etomoxir	or	INF-β	as	a	control.	The	animals	treated	
with	 the	 CPT1a	 inhibitor	 showed	 down-regulated	 inflammatory	 responses,	 ameliorated	
EAE	 symptoms	 as	 well	 as	 remyelination	 of	 CNS	 neurons	 compared	 to	 INF-β	 treated	
animals.	 The	 authors	 conclude	 that	 CPT1a	 mutations	 in	 humans	 may	 protect	 from	
developing	MS.	 Furthermore,	 the	 results	of	 etomoxir	 treatment	 in	mice	and	 rats	might	
provide	first	 insights	 into	the	benefit	of	targeting	 lipid	metabolism	for	therapy	and	with	
that	 alleviating	 MS	 symptoms	 and	 progression.	 Interestingly,	 Shriver	 and	 Manchester	
showed	 a	 similar	 effect	 in	 EAE-induced	 mice	 where	 etomoxir	 treatment	 ameliorated	
disease	 symptoms	 and	 induced	 a	 decrease	 in	 pro-inflammatory	 cytokine	 production	 as	
well	as	CNS	inflammation	[160].		
Raud	 and	 colleagues	 most	 recently	 published	 data	 on	 differing	 effects	 of	 the	 CPT1a	
inhibitor	 etomoxir	 on	 regulatory	 and	 memory	 T	 cells	 [161].	 The	 authors	 showed	 that	
CPT1a	is	not	required	for	effector	and	memory	T	cell	responses	as	well	as	the	suppressive	
function	of	regulatory	T	cells.	They	hint	to	potential	CPT1a-independent	off	target	effects	
of	 etomoxir	 and	 with	 that	 suggest	 additional	 pathways	 involved	 in	 mitochondrial	
impairments	in	EAE-induced	mice,	which	require	further	detailed	analyses.	Especially	the	
effect	 of	 etomoxir	 dose	 in	 varying	 T	 cell	 subtypes	 requires	 further	 analyses.	 Here,	






impairments	 in	 T	 cell	 subsets	may	 also	 involve	 impairments	 in	CPT1a	mRNA	 to	protein	
translation	processes.	To	date,	common	modifications	in	gene	to	protein	translation	are	
known.	 They	 include	 post-transcriptional	 and	 post-translational	 processes	 or	 subunit	
protein	modifications	 (comprehensively	 reviewed	 in	 [71],[162]–[164]).	 Increased	 CPT1a	
protein	 abundance	 may	 signal	 the	 inhibition	 of	 CPT1a	 gene	 transcription	 and	 protein	
translation.	 Furthermore,	mitochondrial	morphology	modifications	 involving	 fusion	 and	
fission	 processes	 that	 have	 most	 recently	 been	 described	 in	 the	 context	 of	
immunometabolism	in	T	cells	[63]	may	provide	explanations	for	the	observed	difference	
in	 mRNA	 and	 protein	 abundance	 of	 CPT1a.	 Buck	 and	 colleagues	 describe	 that	
mitochondrial	 fission	 seems	 essential	 for	 increased	mitochondrial	 energy	 production	 in	
effector	T	 cells	 [63].	A	decrease	 in	mitochondrial	 respiratory	capacity	may	 therefore	be	
associated	 with	 compromised	 mitochondrial	 fission	 and	 fusion	 processes	 as	 well	 as	
mitochondrial	protein	abundance.	Furthermore,	impaired	mitophagy	processes	leading	to	
increased	 cellular	 ROS	 levels	 and	 damaged	 mitochondria	 as	 described	 by	 Pua	 and	
colleagues	may	 influence	T	 cell	 function	with	 increased	mitochondrial	DNA	and	protein	
abundance	[68].	However,	future	analyses	require	additional	detailed	detection	methods	
like	 immunohistochemical	 and	 microscopy	 analyses	 to	 detect	 potential	 mitochondrial	
morphology	alterations	and	CPT1a	protein	levels	in	MS	patients	T	cells.		
The	availability	of	 fatty	acids	 is	essential	 for	 their	 transport	 into	mitochondria	by	CPT1a	
and	 with	 that	 energy	 production	 via	 OXPHOS.	 In	 this	 thesis,	 the	 MS	 patient	 cohort	
showed	a	trend	of	decreased	HDL	serum	levels	compared	to	the	HC	participant	cohort.	In	
MS	 disease,	 the	 contributions	 of	 metabolic	 pathways	 including	 lipid	 metabolism	 to	
disease	 progression	 have	 been	 studied.	 Corthals	 comprehensively	 reviewed	
immunometabolic	 alterations	 in	MS	 and	 proposes	 a	 new	 framework	 for	 understanding	
MS	 disease	 as	 a	 dysfunctions	 of	 lipid	 metabolism	 [165].	 In	 short,	 Corthals	 suggests	 a	
skewed	homeostasis	of	lipid	metabolism	in	immune	cells	during	acute	phase	MS	and	pro-
inflammatory	processes	 leading	to	 increased	cellular	oxidative	stress	and	demyelination	
of	 CNS	neurons.	HDL	 as	well	 as	 associated	 signaling	proteins	have	been	described	 as	 a	
potent	anti-inflammatory	agent	essential	in	cellular	protective	processes	and	contributor	
of	 lipid	metabolism	 in	MS	 disease	 [166]–[169].	 Decreased	 HDL	may	 therefore	 indicate	





have	 proven	 protective	 in	 human	 MS	 and	 murine	 EAE	 models	 [109],[170],[171].	
Therefore,	the	contributions	of	diet	in	MS	disease	should	be	taken	into	consideration.	The	
effects	 of	 glucose	 and	 lipids	 from	 diet	 in	 MS	 patients	 may	 present	 future	 targets	 to	
potentially	assist	MS	immunomodulatory	drugs	and	possibly	alleviate	disease	progression	







non-active	 disease	 phase.	 Increased	 pro-inflammatory	 signaling	 has	 been	 observed	 in	
activated,	proliferating	and	stimulated	T	cells	and	has	even	been	shown	to	contribute	to	
effector	 T	 cell	 subset	 distinguishments	 [172]	 and	 metabolic	 adaptations	 [173].	
Furthermore,	 effector	 T	 cell	 responses	 and	 overall	 cellular	metabolic	 adaptations	 have	
been	shown	to	be	regulated	by	AMPK	signaling	cascades	[174]	including	NFκB	and	TNFα	
pathways,	 which	 are	 central	 pro-inflammatory	 signaling	 pathways	 involved	 cellular	
activation	and	TCR	stimulation.	Cretenet	and	colleagues	have	shown	that	TCR-stimulated	
CD4+	 helper	 and	 CD8+	 effector	 T	 cell	 subsets	 display	 distinct	 immunometabolic	 profiles	
with	 upregulated	Glut1	 expression	 levels	 [172].	 This	 alludes	 to	 the	 assumption	 that,	 in	




Furthermore,	 PD-1	 receptor	 analyses	 were	 performed	 on	 T	 cell	 subpopulations.	 The	
results	complemented	the	data	on	CPT1a	protein	expression	 in	T	cell	subsets	as	well	as	
metabolic	assay	analyses	of	CD4+	and	CD8+	T	cells.		To	date,	to	the	best	of	knowledge,	PD-
1	 expression	 on	 T	 cell	 subpopulations	 alongside	 of	 phenotypic	 analyses	 has	 not	 been	
analyzed	 in	MS	patients.	 	 In	autoimmunity,	 co-inhibitory	T	cell	 receptors	 including	PD-1	




effective	 in	 determining	 cellular	 exhaustion	 in	 auto-immunity	 [104],[146],[175].	 T	 cell	
exhaustion	is	described	to	include	the	loss	of	effector	function,	the	inability	to	transition	
to	 quiescence	 or	memory	 phenotypes,	 a	 transformed	 transcriptional	 profile	 as	 well	 as	
alterations	in	energy	metabolic	signaling	[176].	Especially	PD-1	receptors’	direct	signaling	
interplay	 with	 energy	 pathways,	 TCR	 signaling	 and	 the	 potential	 to	 modify	 cellular	
metabolic	 programs	 in	 T	 cells	 has	 been	 demonstrated	 [177].	 	 Interestingly,	 various	
research	 groups	 have	 described	 immunometabolic	 alterations	 during	 PD-1-mediated	 T	
cell	 exhaustion	 in	 CD8+	 T	 cells.	 Here,	 upregulated	 PD-1	 has	 been	 shown	 to	 drive	 T	 cell	
exhaustion	 in	 chronic	 viral	 infection	 [178],	 a	mechanism	 that	 has	 been	 assumed	 to	 be	
involved	in	MS	disease	development	and	progression	[179].	The	persistent	stimulation	of	
the	TCR,	a	mechanism	of	T	cell	exhaustion,	is	attenuated	by	PD-1	engagement	leading	to	
the	 inhibition	 of	 downstream	 pro-inflammatory	 signaling	 cascades	 involving	 PI3K	 and	
AKT.	The	PI3K-AKT	signaling	cascade	is	a	central	cellular	signaling	pathway	involved	in	e.g.	
cellular	 growth,	 proliferation	 and	 glucose	 metabolism.	 Furthermore,	 Patsoukis	 et	 al.	
showed	 in	 their	 2015	 study	 that	 PD-1	 ligation	 inhibits	 amino	 acid	 transport	 and	
metabolism	 as	 well	 as	 glycolysis,	 while	 inducing	 OXPHOS,	 FAO	 and	 upregulated	 CPT1a	
expression	[177].		
In	the	analyzed	MS	patient	cohort	of	the	current	study,	elevated	CPT1a	protein	levels	in	T	
cell	 subsets	 and	 decreased	 OXPHOS	 and	 glycolysis	 levels	 in	 CD4+	 T	 cells	 were	 not	
accompanied	 by	 differential	 expression	 of	 PD-1.	 Moreover,	 mRNA	 expression	 analyses	
involving	the	PI3K-AKT	signaling	cascades	also	showed	no	difference	in	gene	expression.	
Additional	surface	proteins	indicating	cellular	exhaustions	may	be	an	additional	choice	for	
future	 analyses	 in	MS	 patients	 in	 remission	 and	 could	 therefore	 provide	more	 insights	
into	potential	T	cell	exhaustion	and	its	interplay	with	metabolic	signaling	cascades.	
Finally,	 it	 was	 interesting	 to	 detect	 a	 trend	 of	 decreased	 IL7-Rα	 and	 unaltered	 IL2-Rα	
expression	 in	 conventional	 CD4+	 T	 cells	 from	MS	 patients	 in	 the	 DENIM	 study.	 Various	
research	 groups	 have	 shown,	 that	 IL-7	 cytokine	 binding	 to	 IL7-Rα	 induces	 a	 negative	
feedback	 loop	 including	 the	 down	 regulation	 and	 internalization	 of	 the	 IL-7Rα	 and	
suppression	of	IL-7Rα	gene	expression	[180].	Lawson	and	colleagues	demonstrated	in	the	







This	may	 lead	 to	 the	conclusion	 that	 low	 IL-7Rα	 levels	may	be	beneficial	 in	MS	disease	
progression.	 Furthermore,	 polymorphisms	 have	 been	 described	 for	 the	 IL7-Rα	 [182]	 as	
well	 as	 the	 IL2-Rα	 [183]	 gene	 in	 MS	 patients.	 The	 authors	 show	 that	 in	 murine	 EAE	
models	 and	 human	 analyses,	 these	 genetic	 variants	 contribute	 to	 MS	 disease	
susceptibility.	Gregory	and	colleagues	discuss	their	findings	in	part	by	stating	that	the	IL7-
R	is	essential	in	B	and	T	cell	differentiation	and	therefore	a	potential	gene	target	for	MS	
development	 [182].	 Wang	 and	 colleagues	 state	 that	 IL-2	 is	 essential	 in	 T	 cell	 growth,	
proliferation	and	function	and	alterations	in	its	IL2-Rα	may	be	associated	with	MS	disease	
susceptibility	 and	progression.	However,	 the	 authors	 furthermore	discuss	 that	 previous	




be	 effective	 in	 preventing	 IL-2R	 signaling	 [184]–[186]	 and	 with	 that	 effector	 T	 cell	
activation	[13].	However,	extensive	side	effects	in	more	than	8000	treated	RRMS	patients	




study	 also	 hints	 to	 alterations	 in	 this	 receptor	 and	 potential	 effects	 on	MS	 patients	 in	




suggest	 decreasing	 CPT1a	 protein	 abundance	 in	 CD4+	 T	 cells	 with	 increasing	 disease	
course	and	severity	 in	 the	MS	patient	cohort	compared	 to	 the	HC	participant	cohort.	A	
study	by	Koffman	et	al.	points	out	the	limitations	of	the	progression	index	and	that	it	may	
be	misleading	when	used	for	very	short	or	very	 long	disease	durations	[188].	To	further	













In	 order	 to	 detect	 CNS-mediated	 stress	 response	 mechanisms	 and	 their	 impact	 on	
immunometabolic	 function	 in	 MS	 patients,	 salivary	 cortisol	 level	 as	 well	 as	 gene	
expression	 analyses	 of	GR	 and	GILZ	 mRNA	 were	 performed.	 The	 MS	 patients	 and	 HC	
participants	were	free	of	psychological	comorbidities	including	major	depressive	disorder	
as	 well	 as	 clinically	 significant	 fatigue	 that	 may	 impact	 CNS-related	 analyses.	 Similar	




Alterations	 in	 salivary	 cortisol	 abundance	 throughout	 the	 day	 allude	 to	 impairments	 in	
CNS-mediated	 stress	 response	 mechanisms	 potentially	 affecting	 cellular	 energy	
metabolism	and	immune	response	mechanisms.	In	MS	disease,	the	chronic	activation	of	
immune	response	mechanisms	may	impact	this	sensitive	stress	response	system,	or	vice	
versa,	 and	 further	 deepen	 the	 understanding	 of	 the	 relationship	 of	 CNS	 and	 immune	
system	interactions	in	MS	disease	onset	and	progression.	A	study	by	Gold	et	al.	showed	
that	 salivary	 cortisol	 levels	are	not	altered	between	HC	participants	and	non-depressed	
MS	patients	[122].	The	authors	further	analyzed	MS	patients	with	associated	depressive	
symptoms	and	detected	elevated	evening	cortisol	 levels	compared	to	HC	participants.	A	
study	 by	 Powell	et	 al.	 demonstrated	 elevated	morning	 cortisol	 levels	 in	 RRMS	patients	
compared	 to	 HC	 participants	 [189].	 The	 authors	 further	 demonstrated	 that	 reported	
fatigue	levels	were	associated	with	lower	morning	cortisol	levels	in	MS	patients,	however,	




levels.	 Similar	 results	 of	 increased	 morning	 cortisol	 levels	 in	 MS	 patients	 and	 disease	
progression	 have	 been	 shown	 by	 Kern	et	 al.	 [190],[191].	 The	 results	 of	 the	mentioned	
studies	 demonstrate	 that	 alterations	 in	 HPA	 axis	 activity	 may	 be	 associated	 with	
symptoms	 like	 fatigue	 and	 comorbidities	 like	MS-associated	 depression	 in	MS	 patients	
and	 not	 directly	 associated	 to	 MS	 disease.	 The	 DENIM	 study	 examined	 patients	 in	
remission,	without	major	 physical	 comorbidities	 and	psychological	 illnesses,	which	may	
be	 an	 indicator	 of	 the	 observed	 levels	 of	 morning	 and	 evening	 cortisol	 that	 were	
comparable	to	the	ones	measured	in	the	HC	participant	cohort.	
While	 cortisol	 levels	were	 comparable	 between	 both	 cohorts	 in	 the	 current	 study,	MS	
patients	showed	alterations	 in	GR	and	GILZ	gene	expression	 levels	 in	MS	patients’	CD4+	





effects	 involved	 in	 the	 regulation	 of	 T	 cell	 activation	 and	 preventing	 TCR-activated	
apoptosis	 [97].	This	prevention	of	TCR	activation	has	also	been	shown	to	prevent	NFκB	
activation	 and	 nuclear	 translocation	 to	 further	 initiate	 pro-inflammatory	 cell	 signaling	
cascades	 [97].	 The	 downregulation	 of	 the	 GR	 was	 observed	 in	 immune	 cells	 that	 are	
preventing	 extracellular	 GC	 binding	 with	 respect	 to	 TCR	 activation	 (comprehensively	
reviewed	 in	 [192]),	 thereby	 inhibiting	 CNS-mediated	GC	 influence	 and	 the	 induction	 of	
anti-inflammatory	 signaling.	 Furthermore,	 T	 cell	 cortisol	 response	 and	 resistance	by	GR	
downregulation	has	been	shown	to	be	altered	in	the	murine	EAE	model.	CNS	infiltrates	of	
T	 cells	 in	 EAE-induced	 mice	 showed	 increased	 GC	 resistance	 with	 downregulated	 GR	
which	preceded	CNS	infiltration	and	clinical	symptoms	[193].		
The	 data	 provided	 in	 the	 current	 study	 resulted	 from	 peripheral	 blood-derived	 T	 cells	
from	 MS	 patients	 in	 remission	 without	 major	 comorbidities	 and	 medications.	 The	
observed	 modifications	 in	 GR	 and	 GILZ	 gene	 expression	 allude	 to	 alterations	 in	












studied	 in	 order	 to	 obtain	 energy	 metabolic,	 phenotypic,	 protein	 level	 and	 gene	






to	 define	 the	 cellular	 composition	 of	 the	 non-CD4+/CD8+	 T	 cell	 fraction	 analyzed	 in	
metabolic	 and	 gene	 expression	 assays.	Here,	 a	 strikingly	 increased	 frequency	 of	 B	 cells	
and	regulatory	NK	cells	as	well	as	decreased	frequency	of	cytotoxic	NK	cells	was	observed	
in	 the	MS	 patient	 cohort	 compared	 to	 the	 HC	 participant	 cohort.	 CPT1a	 protein	 levels	
were	 increased	 in	 NK	 cell	 subsets	 but	 not	 in	 B	 cells	 of	MS	 patients.	 Finally,	monocyte	
subpopulations	did	not	show	altered	phenotypic	data	or	CPT1a	protein	expression	in	MS	
patients.		
While	 MS	 is	 generally	 considered	 a	 T	 cell-mediated	 disease	 and	 comprehensively	
described	 in	 this	 thesis,	 B	 cells	 have	 gained	 substantial	 interest	 in	MS	 research.	 To	 the	
best	 of	 knowledge,	 to	 date,	 studies	 have	 not	 analyzed	 or	 shown	 potential	 metabolic	
alterations	of	B	cells	in	MS	patients.	








cells.	 	 Clarke	 and	 colleagues	 conclude	 that	 B1	 B	 cells	 adapted	 their	 specific	 functional	
properties	to	the	metabolic	requirements	in	their	tissue-resident	environment.	Mendoza	
and	colleagues	showed	increased	OXPHOS	and	aerobic	glycolysis	upon	germinal	center	B	
cell	 response	 accompanied	 by	 the	 activation	 of	 the	 PI3K-AKT-mTORC1	 pathway	 and	
increased	gene	expression	involving	glucose	metabolism	[195].	Moreover,	as	observed	in	
T	cells	and	TCR	signaling,	cellular	fate	is	dependent	on	B	cell	metabolic	programming	and	
mitochondrial	 activation	 involving	 downstream	 B	 cell	 receptor	 signaling	 cascades	
including	 NFκB	 and	mTORC1	 as	well	 as	mitochondrial	 ROS	 production.	 This	 effect	was	
demonstrated	 by	 Tsui	 and	 colleagues	 in	 their	 2018	 study	 with	 murine	 cells	 [196].	
Impairments	 in	 B	 cell	 metabolism	 and	 activation	 following	 antigen	 exposure	 can	
immediately	 impact	 helper	 T	 cell	 fate	 since	 B	 cells	 function	 as	 APCs	 and	 helper	 T	 cells	
provide	a	secondary	signal	for	strong	B	cell	activation	[196].		
The	 effect	 of	 increased	 B	 cell	 populations	 in	 MS	 patients,	 as	 observed	 in	 the	 current	
study,	 has	 also	been	discussed	by	other	 research	 groups.	 Their	 role	 in	MS	has	become	
evident	by	 the	 success	of	α-CD20	 therapy	 (e.g.	 ocrelizumab,	 rituximab)	 [197].	Baecher-
Allan	 and	 colleagues	discuss	 the	beneficial	 effect	 of	α-CD20	 therapy	by	 the	deletion	of	
pro-inflammatory	 B	 cell	 subsets	 that	 is	 driving	 the	 activation	 of	 T	 cells	 via	 antigen	
presentation	[2].	Furthermore,	they	discuss	the	possibility	of	α-CD20	treatment	to	target	
mature	naïve	and	memory	B	cells	leaving	plasma	cells	and	immature	B	cells	unaffected	in	
MS	 patients.	 Interestingly,	 the	 balance	 of	 pro-inflammatory	 B	 cells	 secreting	 e.g.	 IL-6,	
TNFα,	GM-CSF	and	anti-inflammatory	B	cells	secreting	IL-10	and	IL-35	has	been	shown	to	
be	 altered	 in	MS	 patients	with	 an	 increased	 pro-inflammatory	 phenotype	 [198].	 Li	 and	

















In	 this	 thesis,	 T	 cell	were	 the	 central	 objective	 and	 B	 cell	 subpopulations	 could	 not	 be	
further	 analyzed.	 Future	 analyses	 require	more	detailed	experiments	 to	promote	B	 cell	
subtype	distinguishments	and	B	cell	sorting	for	comprehensive	metabolic	analyses	in	MS	
patients.	 Here,	 the	 role	 of	 B	 cells	 contributing	 to	 T	 cell	 metabolic	 alterations	 and	
immunometabolic	 adaptations	 should	 be	 considered	 closely	 as	 well	 as	 the	 interplay	
between	B	and	T	cell	subpopulations.	
In	addition	to	B	cells,	NK	cells	have	also	been	shown	to	contribute	to	autoimmunity	and	
to	 regulate	 and	 inhibit	 T	 cell	 survival	 in	 MS	 patients.	 In	 the	 current	 study,	 CD56bright	
CD16low	regulatory	NK	cells	were	increased	and	cytotoxic	CD56low	CD16bright	NK	cells	were	
decreased	 in	MS	patients	 compared	 to	HC	participants.	 Cytotoxic	 CD56low	 CD16bright	NK	
cells	compromise	about	90%	of	NK	cells	 in	 the	peripheral	blood	and	are	 found	 in	much	
lower	 frequency	 in	 tissues	 compared	 to	 CD56bright	 CD16low	 regulatory	 NK	 cells	 [2].	
Increases	 in	 CD56bright	 CD16low	 regulatory	 NK	 cells	 were	 observed	 to	 correlate	 with	
immunomodulatory	and	 immunosuppressive	 treatment	response	 in	MS	patients	on	 IL2-









cell	 type	 to	MS	 disease.	 The	 elevated	 CPT1a	 levels	 observed	 in	 the	MS	 cohort	 of	 the	





Monocytes,	 as	 a	 main	 cellular	 component	 of	 the	 non-CD4+/CD8+	 T	 cell	 fraction	
investigated	 in	 this	 study	 should	 finally	 be	mentioned.	 In	 RRMS,	monocytes	 have	 been	
shown	to	induce	T	and	B	cell	responses,	contribute	to	immunoregulation	as	well	as	pro-
inflammatory	cytokine	secretion	and	CNS	infiltration	[203]–[205].	In	the	samples	analyzed	
as	 part	 of	 the	DENIM	 study,	 no	phenotypic	 alterations	 or	 adapted	CPT1a	 expression	 in	
monocyte	subsets	were	detect	in	the	MS	patient	cohort	compared	to	the	HC	participant	
cohort.	 To	 the	 best	 of	 knowledge,	 CPT1a	 expression	was	 analyzed	 for	 the	 first	 time	 in	
monocyte	 subpopulations	 in	 a	 human	 MS	 study	 and	 presents	 primary	 data	 on	 the	
mitochondrial	membrane	protein	expression	 in	 these	 cell	 subsets.	Conclusively,	while	T	
cell	subsets	and	NK	cells	displayed	altered	CPT1a	protein	expression	levels,	this	could	not	
be	 observed	 in	 MS	 monocyte	 subtypes.	 These	 findings	 may	 allude	 to	 metabolic	
adaptations	 highly	 specific	 to	 immune	 cell	 subsets	 in	 MS	 disease	 and	 require	 more	
detailed	investigations.	
The	 gene	 expression	 analyses	 of	 the	 non-CD4+/CD8+	 T	 cell	 fraction	 performed	 in	 the	




first	 insight	 into	 immunometabolic	 alterations	 in	 the	 cell	 types	 making	 up	 the	 non-




will	 further	 deepen	 the	 understanding	 of	 immunometabolic	 signaling	 cascades	 in	








While	 the	 DENIM	 study	 provides	 a	 robust	 MS	 patient	 and	 carefully	 matched	 HC	
participant	 cohort,	 there	 are	 limitations	 that	 require	 mentioning.	 The	 diversity	 of	
medications	 taken	 by	 the	 MS	 patients	 did	 not	 allow	 valid	 and	 significant	 statistical	
analysis	 regarding	 the	 effect	 of	 individual	 types	 of	 medications	 on	 the	 analyzed	
immunometabolic	 functions.	 Furthermore,	 sex	 differences	 could	 not	 be	 statistically	
analyzed	due	to	the	limited	MS	patient	and	HC	participant	sample	size.	In	future	clinical	
studies	the	effect	of	medication	and	sex	should	be	examined	carefully	whenever	possible	
due	 to	 the	 strong	 evidence	 of	 both	 factors	 influencing	 MS	 disease	 susceptibility,	
development	and	progression	[206]–[209].	 It	 is	 important	to	note	that	the	DENIM	study	
provided	 comprehensive	 data,	 however,	 the	 analyses	 performed	 were	 limited	 by	 the	
availability	of	biomaterial,	especially	of	sorted	T	cells.		
The	 blood	 samples	 were	 processed	 following	 strict	 standard	 operating	 procedures	
allowing	freezing	and	subsequent	pairwise	MS	patient	and	HC	participant	analyses	for	all	
laboratory	 techniques	 performed.	 The	 metabolic	 assay	 was	 also	 established	 after	
comprehensive	 testings.	 However,	 freezing	 procedures	 have	 been	 shown	 to	 impact	
immune	 cell	 quality	 [124]	 and	 analyzing	 fresh	 samples	 in	 metabolic	 assays	 may	 be	
desirable	in	order	to	receive	even	higher	quality	readouts.		
In	healthy	individuals,	different	T	cell	subpopulations,	e.g.	effector	T	cells,	memory	T	cells	
or	 Tregs,	 have	 been	 shown	 to	 rely	 on	 distinctive	 metabolic	 programs	 based	 on	 their	
specific	cellular	demands	and	requirements.	Therefore,	future	studies	should	analyze	MS	
patients’	CD4+	 and	CD8+	 T	 cell	 subpopulations	 to	narrow	down	specific	 cell	 subsets	and	
observe	differences	in	metabolic	function.	Considering	the	alterations	in	frequencies	of	B	
cells	and	NK	cell	subpopulations	in	MS	patients,	more	detailed	cell	subset	phenotyping	of	
B	 cells,	 including	 the	 memory	 compartment,	 should	 be	 performed	 as	 well	 as	












More	 comprehensive	 RNA	 analysis	 techniques	 including	 microarray	 analyses	 may	 be	
considered	in	future	investigations	allowing	a	more	comprehensive	exploration	of	genes	
and	with	that	providing	information	about	signaling	cascades	involving	inflammatory	and	
metabolic	 signaling.	 Here,	 the	 difference	 of	CPT1a	 mRNA	 gene	 expression	 and	 protein	
abundance	 should	 be	 considered	 to	 help	 to	 understand	 the	 impact	 on	 immune	 cell	
function,	especially	 in	CD4+	T	 cells.	Additional	protein	quantification	methods,	e.g.	 SDS-
PAGE	 (sodium	 dodecyl	 sulfate-polyacrylamide	 gel	 electrophoresis)	 and	 Western	 Blot	
analyses	 or	 broad	 proteomic	 screenings	 for	 CPT1a	 will	 add	 quantitative	 data	 to	 the	
observed	results.	Immunohistochemical	microscopy	analyses	of	CPT1a	as	well	as	staining	
mitochondria	 would	 also	 provide	 quantitative	 data	 on	 CPT1a	 abundance	 and	
mitochondrial	 morphology	 within	 T	 cell	 subpopulations.	 This	 data	 could	 allude	 to	
potential	impairments	in	mitochondrial	fusion,	fission	and	mitophagy	processes	and	their	
impact	on	 immunometabolic	function	 in	MS	patients.	Additionally,	sequencing	of	CPT1a	
may	be	performed	complementing	 the	 results	 in	 the	EAE	animal	model	 [157],[211]	and	
potentially	detecting	SNPs	in	the	CPT1a	gene.	
	
In	 upcoming	 clinical	 studies,	 it	 will	 be	 interesting	 to	 see	 how	 the	 inflammatory	 and	
metabolic	 profile	 changes	 in	 phases	 of	 relapses	 in	 RRMS	 patients	 and	 how	 the	
mitochondrial	 signaling	 pathways	 including	 the	 CPT1a	 protein	 may	 be	 altered	 during	
disease	 progression.	 Furthermore,	 the	 involvement	 of	 different	 energy	 pathways	 in	
immune	cell	subpopulations	in	relapses	should	be	analyzed	to	broaden	the	understanding	
of	 the	 interplay	 between	 cellular	 energy	 metabolism	 and	MS	 disease	 progression	 and	
finally	 lead	 to	potential	 therapeutic	 targets.	 Finally,	MRI	 imaging,	 as	 the	most	 common	
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Figure	 35:	Within	 group	 comparisons	 of	 differential	 blood	 parameters	 in	MS	patients	 and	HC	
participants.	 Whole	 blood	 was	 analyzed	 in	 a	 certified	 routine	 laboratory:	 Labor	 Berlin,	 Berlin,	
Germany.	 Blood	 was	 drawn	 after	 a	 12	 hour	 fasting	 period	 and	 analyzed	 on	 the	 same	 day.	





































Figure	36:	CD4+	and	CD8+	memory	T	 cell	 subpopulations	do	not	 show	differences	 in	 frequency	










cell	 subpopulations:	 CCR4+,	 p=0.31.	 CCR6+,	 p=0.03.	 CXCR3+,	 p=0.83.	Wilcoxon	 signed-rank	 test,	
Appendix	
138	
medians	 with	 interquartile	 ranges	 are	 displayed.	 CCR:	 CC	 chemokine	 receptor,	 CXCR3:	 CXC	
chemokine	receptor3,	Th:	helper	T	cell,	HC:	healthy	control,	MS:	multiple	sclerosis.		
Figure	 38:	 Increased	 frequency	 of	 B	 cells	 in	 live	 lymphocytes	 population	 in	 MS	 patients	
compared	to	HC	participants.	Between	group	analyses	of	CD20+	CD56+	B	cells	of	MS	patients	and	
HC	 participants,	 n=29	 pairs,	 p=0.0086.	 Displayed	 values	 in	 the	 flow	 cytometry	 blots	 are	
frequencies	 of	 CD20+	 cells	 expressed	on	 live	 lymphocytes	 from	a	 representative	MS	patient-HC	
participant	pair.	Wilcoxon	signed-rank	test,	medians	with	 interquartile	ranges	are	displayed.	HC:	
healthy	control,	MS:	multiple	sclerosis.	
Figure	39:	 Frequency	of	 cytotoxic	and	 regulatory	NK	cells	n	NK	 cell	population	 in	MS	patients	
shows	 significant	 differences	 compared	 to	 HC	 participants.	 Between	 group	 analyses	 of	 MS	










subpopulations:	 naïve:	 p=0.12.	 CM:	 p=0.15.	 EM:	 p=0.41.	 TEMRA:	 p=0.88.	 CD8+	 T	 cell	
subpopulations:	 naïve:	 p=0.18.	 CM:	 p=0.11.	 EM:	 p=0.27.	 TEMRA:	 p=0.69.	Wilcoxon	 signed-rank	
test,	medians	with	interquartile	ranges	are	displayed.	CM:	central	memory,	EM:	effector	memory,	
TEMRA:	 terminally	 differentiated	 effector	 memory	 cells	 re-	 expressing	 CD45RA,	 HC:	 healthy	
control,	MS:	multiple	sclerosis.	
Figure	41:	B	cells,	NK	cells	and	monocyte	subpopulations	analyzed	by	flow	cytometry	for	CPT1a	
MFI.	 (A)	Between	group	analyses	 for	MS	patients	and	HC	participants	are	 shown.	n=29	pairs.	B	
cells	 p=0.40.	 cytotoxic	 NK	 cells.	 regulatory	 NK	 cells.	 CD14++	 CD16-	 classical	 monocytes.	 CD14++	
CD16+	intermediate	monocytes	n=27	pairs.	CD14+	CD16++	non-classical	monocytes	n=27	pairs.	(B)	
CPT1a	expression	in	the	corresponding	cell	subsets	of	a	representatice	MS	patients-HC	participant	
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